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RESUMÉ
Les adénovirus en combinaison avec des gènes suicides sont parmi les
modalités thérapeutiques les plus applicable pour le traitement du cancer. Un des gènes
suicides couramment utilisés pour la thérapie génique du cancer est le HSV-TK. Dans
le cadre de mon projet de recherche, nous avons cherché à améliorer l’approche
thérapeutique du gène suicide HSV-TK par la coexpression de la guanylate kinase (GK).
À cette fin, nous avons construit deux adénovirus: un co-exprimant la gène de la TK et
le gène rapporteur GFP; et l’autre, co-exprimant le gène de la 1K et celui de la GK; ces
gènes étant contrôlés par le promoteur inductible CMV5(CuO). Nos résultats ont
démontré que l’activité de la combinaison TK-GK était équivalente et non supérieure à
celle de TK seule; et cela, dans différentes lignées de cellules cancéreuses comme le
glioblastoma humain U87 et la lignée de tumeur ovarienne TOV21G. Nous avons de
plus démontré qu’il n’en était pas différent avec des cellules normales (comprenant les
cellules fibroblastes humaine MRC-5 et les cellules endothéliales de veine ombilicale
humaine Huvec). Ainsi, nous avons conclu que dans les modèles étudiés, l’activité GK
ne potentialise pas la cytotoxicité du gène 1K.
J’ai aussi évalué différentes stratégies pour la construction de virus réplicatifs.
Nous avons cherché la meilleure stratégie pour insérer un transgène (GFP) près de la
région E4 de l’adénovirus, afin de conserver intact la région El qui est essentielle pour
la réplication du virus. Le clonage de transgènes dans la région E4 affecte la réplication
du virus et l’expression du transgène. J’ai démontré qu’une configuration où un
promoteur inductible CR5 contrôle l’expression du transgène orienté vers l’IIR de
gauche représente la meilleures option pour optimiser la production virale (i.e. son titre)
et l’expression du transgène. Enfin, contrairement à un autre gène suicide étudié dans
notre laboratoire, nous avons déterminé que la surexpression du gène 1K, obtenue en
augmentant la charge virale ou par réplication du virus, n’améliore pas l’activité
cytotoxique dans les cellules U87. Ainsi, l’augmentation de l’activité du gène de la 1K
par la réplication, ou par la combinaison avec la GK n’a pas d’incidence sur l’activité
cytotoxique; suggérant que l’activité de la 1K n’est pas le facteur limitant.
Mots clés : vecteurs adénoviraux, thérapie gènique du cancer, gènes suicide, pro-drogue,
promoteur inductible, cumate
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ABSTRACT
The adenoviruses in combination with the suicide genes are among the most
applicable forthcoming therapies for cancer treatment. HSV-TK is one of the well
smdied suicide genes that are currentiy tested for cancer treatment. In this project, we
tried to improve the therapeutic effect of the suicide gene HSV-TK via its coexpression
with guanylate kinase (GK). In order to achieve that, we constructed two adenoviruses:
one coexpressing TK with the reporter gene (GfP), and the other, coexpressing TK and
GK, which genes are controlled by CMV5(CuO) inducible promoter. Our resuits showed
that the activity of the combination of TK-GK was equivalent to TK alone in different
cancer ceil lines including human gliobiastoma (U87) and ovarian ccli unes (10V2 1G).
We also demonstrated there were no difference in the activity of both viruses in normal
celis as well (such as human fibroblast cells MRC-5 and human umbilical vein
endothelial ceils Huvec). In conclusion, we determined that in our platform, the activity
ofGK does flot improve the cytotoxic effect of 1K gene.
We aiso evaiuated different strategies for construction of the replicative
viruses. We looked for the best strategy to insert our transgene (GFP) in the vicinity of
the E4 region of the adenovirus, in order to conserve the Fi region, which is essential
for the replication of the adenovirus. In general the cloning of the transgene in the
vicinity of the E4 region affects the replication of the adenovirus and the expression of
the transgene. We demonstrated that the configuration in which the inducible promoter
CR5 controls the expression of the transgene oriented toward the ieft TIR represents the
best option for optimizing the viral production (i.e. the titer) and the transgene
expression. Finally, in contrast to another suicide gene studied in our laboratory, we
determined that the overexpression of TK gene in U$7 celis, obtained from the
increasing MOI or through replication, did flot improve the cytotoxic activity nor the
bystander effect. In conclusion, increasing the activity of the 1K gene via replication or
combination with another suicide gene (GK) has no incidence on cytotoxic activity;
suggesting that the activity of 1K is not a limited factor.
Key words : adenoviral vectors, cancer gene therapy, suicide genes. prodrug, inducible
promoter,cumate
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Chapter 1:
Introduction
21.1 Gene therapy
Gene therapy, which emerged in the late 1980’s to early 1990’s, as part of
modem molecular medicine holds great promise for the treatment of both acute and
chronic diseases. It has proved by now its potential in a number of clinical trials aimed to
develop a cure for several inherited and acquired genetic disease including various type
of cancer, coronary artery disease, and cystic fibrosis (1;2). Gene therapy is essentially an
approach that aims at correcting defective genes responsible for disease development, in
which the delivered gene enters the ceils and tums them into small factories that produce
a therapeutic protein for a specific disease.
Despite the numerous encouraging resuits demonstrated by gene therapists so
far, this teclmology is presently facing very serious obstacles associated with the
development of the technical means to deliver corrective genes to the site of the disease
in a safe and efficient manner. These obstacles include: poor delivery efficiency. high
cost, time-consuming vector preparation, toxicity. immunogenicity, and oncogenicity, as
well as short-term transgene expression and poor expression levels.
1.2 Gene de]ivery methods
Two distinct methods of delivering the therapeutic genes are possible. Gene
transfer can be carried out ‘in vivo where the vector containing the expression cassette
is delivered directly to target cells within the individual. Altematively, due to the
inability of certain vectors to infect or reacli the target tissue, cells are removed, grown in
vitro, and infected/ transfected with the recombinant vector. The altered cells producing
the foreign protein are then transplanted back into the patient, which is known as ‘ex
vivo’ gene therapy.
There are essentially two types of gene delivery vehicles, known as vectors
including non-viral and viral vectors. In both cases, the gene of interest is first placed in
3the vector, which is capable of delivering the gene into specific target celis for its
expression. Non-viral methods make use of cationic lipids, polymers, targeting proteins,
and calcium phosphate, as well as mechanical methods such as electroporation. Non-
viral vectors were utilized as safer alternatives for gene delivery in vitro and ex vivo but
their success for in vivo gene therapy lias been limited due to 10w efficiency and safety
issues. Viral methods make use of genetical!y engineered retroviruses, adenoviruses,
adeno- associated virnses (AAVs), and other viruses that have been optimized for
facilitated gene transfer procedures. However, the use of viral vectors was narrowed due
to the safety concems. There is no single best method for ail applications.
There are certain stringent criteria for a candidate gene delivery system or
“vector”. first, the vector shou!d be stable in vivo for a time period sufficient to achieve
gene delivery. Second, administration of the vector should flot be associated with a
significant host immune response or toxicity.
1.2.1 Non- viral vectors
Non-viral gene delivery is an important approach in order to stab!ish safe in
vivo gene therapy in clinic. The use of non-viral delivery methods has become routine
for ceil unes grown in vitro due to tlie simplicity and relative!y high efficiency of gene
transfer in a wide range of ce!! lines. However, due to some of the disadvantageous
features, their application in vivo is limited. Non- viral vectors have a very !ow gene
transfer efficiency compared to the vira! vectors. Thus. except for the most reca!citrant
ce!! !ines, non-viral gene transfer lias become the method of choice for ce!! lines grown
in vitro. There are several options for non- viral gene delivery. The simp!est method is
the direct introduction of therapeutic DNA into target ce!!s. This approach is !imited in
its application because it can be used only with certain tissues and requires !arge amount
of DNA. Another non- vira! approach invo!ves creation of an artificial !ipid sphere with
an aqueous core. A wide variety of lipid molecules used as gene carriers bas been
reported and cornpared over the !ast twenty years. The !iposomes, which carry the
4therapeutic DNA, are capable of passing the DNA through the target ceil membrane via
the endocytotic process. Therapeutic DNA can also get inside target celis by chemically
linking the DNA to a molecule that wiÏY bind to specific celi receptors. Once bound to
these receptors, the therapeutic DNA constructs are engulfed by the ccli membrane and
passed into the interior of the target celi.
1.2.2 ViraI vectors
Gene therapy bas evolved due to the development of a number of bioteclmology
weapons including viral vectors that lead to a longer expression of the transgene. The
viral vectors used as gene delivery vehicles include retroviruses, adenoviruses, adeno
associated viruses, herpes simplex viruses, vaccina viruses and more recently the
lentiviruses. In contrast to non- viral vectors. virai vectors are generally more efficient in
terms of percentage of cells transduced, are more complex and time-consuming to
prepare, and require a greater degree of expertise in handiing.
Today, the two most widely used viral vectors for gene therapy, are the
retroviruses (RVs) and adenoviruses (AdVs). RVs are capable of integrating the host’s
genome and give a permanent expression of the recombinant gene. However, they are
difficuit to grow to high titres and purify for direct administration, which require the
patient’s cells be cultured and transduced in vitro. Finally, there is aiways the risk of
insertional mutagenesis and/or activation of ceilular oncogenes. Replication defective
vectors derived from simple retroviruses or the most complex genomes of lentiviruses
continue to offer the advantages of long term expression, ccli and tissue specific tropism
for the deiivery ofthe therapeutic genes (3).
AdVs on the other hand, are not integrated into the host genome and shown transient
expression in dividing celis but longterm expression in quiescent ceils such as muscular
cells. AdVs are one of the most studied viral vectors, which are considered as one of the
best gene delivery vehicles developed so far.
51.3 Adenovirus Biology
1.3.1 Historical perspective
Adenoviruses have been first isolated and characterised in the early 1950’s by
Row et aï, in an attempt for the study of the causal agent of acute respiratoiy infections.
They observed the spontaneous degradation of primary celi cultures extracted from
human adenoids. In 1954 Hilleman and Wemer isolated agents from respiratory
secretions that induced cytopathic changes in cultures of human celis while studying an
epidemic of respiratory illness among army recruits. In 1956, the term adenovfrus was
designated for those viral agents, due to the original source of the tissue (adenoid) from
which the virus was isolated. Adenoviruses are a frequent cause of acute upper
respiratory tract (URT) infections. In addition, they also cause a number of other types of
infections.
1.3.2 Classification
Adenoviruses belong to the family of Adenoviridae. This farnily is subdivided
into two genera, Mastadenoviruses and Aviadenoviruses. Aviadenovirus genus is limited
to viruses of birds, and Mastadenovirus genus includes a wide variety of viruses such as
human, simian, bovine. equine, porcine, ovine, canine, and opossum viruses. To date, 47
human adenovirus serotypes have been isolated based on the type-specific neutralization
by antisera which resuits predominantly from antibody binding to epitopes on the virion
hexon protein and the terminal knob portion of the fiber protein (4). Each serotype was
then classified into one of the six subgroups (see Table I), A-F, based on their ability to
agglutinate red blood cells. Among ah of the serotypes, group C viruses are the most
studied in virology and molecular biology, which are non-tumorigenic and consist of
AdV group C viruses serotypes 1, 2, 5 and 6. The serotypes 2 and 5 (AdV2 and AdV5)
are most commonly used for gene delivezy vector development.
6Subgroup Hemaggiutination Serotypes Oncogenic potential
groups
Tumors in Transformation
animais in tissue culture
A IV (httieornoagglutination) 12,18,31 High +
B I (complete agglutination 37,11,14,16,
cf monkey 21,34,35 Moderate +
erythrocytes)
C lii (partial agglutination 1,2,5,6 Low or none +
of rat erythrocytes)
D II (complete agglutination 8,9,10,13, Low or none
cf rat erythrocytes) 15,77,19,20,22—30, (mammary
32,33,36—39,42—47 tumors) +
E III 4 Lowornone ÷
F III 40,41 Unknown
Table I: classification of human adenoviruses (Adapted from Shenk, T, 1996)
1.3.3 Morphology
Ail adenovirus particles consist of non-enveloped. icosahedral protein capsids
with a diameter of 60-90 nm and the inner DNA/protein cores. 13% of the particle mass
is DNA and the remaining 87% are proteins. The outer capsid is composed of 252
capsomers: 240 hexons and 12 penton base subunits. The hexon consists ofa trimer of
the major polypeptide II with a central pore. Polypeptides VI, VIII, IX and liTa are
known as the minor peptides and ail play associated structural roles in the outer sheli.
Polypeptides VI, VIII and IX are associated with the hexon and seem to be involved in
stabilising the Hexon capsomers. Polypeptide Illa seems to function as a linker between
the viral capsid and the core and ultimately in viral assembly. Five copies of poiypeptide
II are associated to form the penton base protein, which is found at each vertex of the
icosahedral particle and act as a base for the fiber protein. Polypeptide IV forms the
trimeric fiber protein, which projects from the penton base at each vertex of the
icosahedron (5). The trimeric fiber proteins are responsible for recognition and binding
to a 46-kDa transmembrane cellular protein known as coxsackie/adenovirus receptor
(CAR), while the penton base recognizes the cellular integrins (avf33 and Œvf35) and
helps in the intemalization step (6). The core of the virion is composed of four known
proteins and the viral genome. Polypeptides V, VII and mu are the first three proteins,
which are in contact with the viral DNA. Polypeptide VII is known as a predominant
7protein of the core with about 1000 copies present per virion, positively charged and
extensively associated with viral DNA. The fourth protein, which is known by the name
of terminal protein, is attached to the 5’ ends of the viral DNA, by a phosphodiester
bond. The terminal protein plays an important role in DNA replication and mediates
attachment of the viral genome to the nuclear matrix (7). Viral protease, the cysteine
protease L3/P23, is located in the internal cavity at about 10 copies per virion. The PS
encoded in the late cassette L3 as a 23 KDa polypeptide and is essentiai during the
maturation and assembly of the virus in the nucleus of infected cells as well as for the
uncoating during entry into the host ceIl (8).
1.3.4 Genome organization
All adenovirus genomes are linear, non-segmented, double stranded DNA of
36 Kbp long and are divided into 100 map units (mu). Each end of the viral genome has
a 100- to 150- base pair (bp) repeated DNA sequence known as inverted terminal repeat
(ITR). The ieft end contains the signal for encapsidation (packaging signal). Both of the
ITRs and the packaging signal are the cis-acting elements, which are necessary for virat
DNA replication and packaging (9).
The viral genome is composed of five early transcription units (E1A, E1B, E2,
E3 and E4), two delayed early units (IX and Iva2) and one late unit, which generates five
families of late mRNAs (Li to L5) (see Figurel).
The El region (E1A and E1B) encodes proteins responsible for the regulation
of transcription of the viral genome and of a few cellular genes. E 1 A is the first gene to
be transcribed directly afier infection. Transcription of the E1A unit is controlled by a
constitutively active promoter that includes a duplicated enhancer element. This gene
codes for two different components sharing substantiai sequences that are termed as
289R or (13$) and 243R or (12$) based on the number of amino acid residues. Those
proteins are trans-acting transcriptional regulatory factors. which are necessary for
transcriptional activation of early genes. Moreover the E1A proteins are primarily
8concemed with modulating cellular metabolism to make the ceil more susceptible to
virus replication by inducing the host celi to enter the S phase ofthe cell cycle (10). The
F13 gene codes for two different proteins known as EÏBÏ9KDa and E1B55KDa. Like
FiA proteins, the E1B proteins aiso modulate ccli cycle progression via targeting the
ceilular p53 tumour suppressor protein, which regulates progression from Gi to S. The
E1B-55KDa protein binds to p53 within infected cells and it can block transcriptionai
activation by p53. The E1B19KDa gene product is analogous to the cellular Bd-2 gene
and is concerned with prolonging celi survival via an interaction with the Bax family
(whose transcription can be promoted by p53) (11). The E 13-55 KDa protein also
complexes with the ORF6 protein from the F4 region to modulate expression ofthe viral
late genes.
Expression of the E2 region (E2A and E2B) ieads to the synthesis of the DNA
polymerase, pre-terminal protein and DNA binding proteins needed for viral DNA
replication. The E3 genes, which are dispensable for the replication ofthe virus, code for
proteins invoived in counteracting the immune system aller an adenoviral infection. The
E3 gp I9KDa protein binds to the MHC class I heavy chain and prevents its transport to
the ccli surface, thereby inhibiting the differentiation of cytotoxic T lymphocytes
directed against viral antigens (12). The E3-RID compiex containing RIDŒ and RIDI3, a
membrane protein, inhibits Fas induced apoptosis by intemalizing Fas from the cdl
surface into lysosomes where Fas is degraded. The E3-14.7 KDa, a non-membrane
protein, is involved in inhibition of TNf-induced apoptosis by interacting with cellular
proteins in TNfR1- caspase pathway. The F4 transcription unit ofAd is located between
map units 91.3 to 99.1 at the right hand end of the Ad genome and is transcribed in the
lefiward direction and is controled by the F4 promoter. The gene products derived from
the F4 cassette terrned ORF1, ORF2, ORF3, ORF3/4, ORF4, ORF6 and ORF6/7. They
are mainly involved in viral DNA replication, late viral protein synthesis, shut offofhost
protein synthesis, production of progeny virions and preventing concatemer formation of
viral genomes. Ad mutants that lack the entire E4 region or that fail to express ORF6 and
ORF3 proteins are severely restricted for growth. These mutants show a complex
phenotype, which includes a defect in virus particle assembly, failure to accumulate
9normal nuclear and cytopÏasmic levels of late messages and late protein synthesis, and
failure to shut off host macromolecular synthesis at late times (13). It has been shown
that the viruses that contain mutations in both ORF3 and ORF6 are as defective as the
E4-deleted viruses. Other studies have shown that ORF3 and ORF6 can partially
compensate for each other’ s defects and are involved in enhancing of late gene
expression through nuclear stabilization of late mRNAs and indirectly increase the
efficiency of viral DNA synthesis (14). The product of the late gene is expressed afier
processing a 20-Kbp primary transcript driven by the major late promoter (MLP). This
large transcription unit is then processed by differential poly (A) site and spiicing in
order to generate 1$ mRNAs. Those rnRNAs are grouped into five families called LI
L5 ail ofwhich are responsible ofproducing the viral capsid proteins (9).
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Figure 1: AdV5 genome structure and essential cis elements. The length ofthe AdV5
is 36 Kbp, divided into 100 mu. The upper strand is the r-strand and the lower strand is
the 1-strand. Black squares at the ends of both strands represent ITRs. The arrows
represent different transcription units. The ernpty box on top represents the location of
the MLP and tripeptite leader sequences. The lefi cis elements, inciuding the ITR and
packaging signal (P), are enlarged; in addition, the positions of the A-repeat motifs of
the packaging sequences are shown (9).
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1.3.5 Replication cycle
AdV is typical of lytic DNA viruses. The replicative cycle of Ad starts from
entering celis and ends at release from the lyzed, infected celis. The terminal globular
domain or “knob” region of the homotrimeric fiber of the Ad capsid is responsible for
the primary virus attachment to the cellular receptor, the coxsackie and adenovirus
receptor (CAR) (15). Following the initial attachment, the interaction between an RGD
motif of the penton base protein with a cell surface integrin molecule (Œj3i, Œvf33, Œv135),
serving as a secondary or intemalization receptor, triggers the virus uptake by clathrin
dependent receptor-mediated endocytosis (16). The endosomal uptake of the virus and
release into the cytoplasm is accompanied by a stepwise dismanteling of the capsid,
leading to the microtubule assisted transport and finally very efficient delivery of the
core protein-coated genome to the nucleus. These may involve interactions with surface
receptos, exposure to low pH in endosomes or association with intracellular factors. It
has been shown that for capside dissociation and genome release the structural protein
VI has to be degraded by the viral L3/P23 protease (17). The transport of viral DNA to
the nucleus consists of the binding of the terminal protein to the nuclear matrix and entry
of the genome into the nucleus in association with one or more NLS- containing
proteins. There are three steps for the replication cycle, which are the early transcritional
phase, DNA replication phase and late transcriptional phase. Three goals are
accomplished at the first phase of the early transcriptional phase: firstly. to create an
optimal environment for viral replication by expression of the E lA and E 1 B gene
products which play a role in the induction of the host ceil to enter the S phase of the cell
cycle: secondly, to protect the infected celis from the antiviral defense system ofthe host
by expressing the products of E3 gene: thirdly, to express the viral gene products that are
essential for viral DNA replication.
During DNA replication phase, four virus- encoded proteins are known to be
involved. TP, a 55 KDa terminal protein, that acts as a primer for initiation of synthesis,
AdDBP, that is a DNA binding protein, and AdDNA POL, which is a I 4OkDa DNA
dependent polymerase. A cysteine protease (L3/P23) plays an important role in
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proteolytic trimming of TP. The special TP/ITR structure serves as the origin of the viral
DNA replication. Chain elongation is completed by two virus E2- coded proteins, the
polymerase and single stranded DNA binding protein and cellular proteins (factor I and
II).
The third phase of the replication cycle is the late transcription, which is
primarily driven by the major late promoter (MLP). The late transcripts (L1-L5) derived
from the MLP promoter possess a 5’ tripartite leader sequence, which make them
preferred over the cellular mRNA for translation.
1.3.6 Viral particle assembly
Assembly of the Ad virion generally begins in the cytoplasm when individual
monomers form into hexon and penton capsomers. Afier their production, hexon and
penton capsomers accumulate in the nucleus where the final assembly of the virion
occurs. The intranuclear virion assembly starts about 8h afier infection and leads to the
production of i04 to i05 progeny particles per ceil, which can be released afier final
proteolytic maturation by celi lysis 30- 40 h post infection completing the viral life cycle.
There are multiple steps along the assembly process: ta) formation of the major
structural unit of capsid (capsorners of hexon and penton), (b) assembly of empty
capsids, (e) insertion of viral DNA into capsids, and (d) proteolytic cleavage of
maturation. The cis- acting packaging domain of AdV5 is Iocated in the lefi end of the
viral genome (194- 380 bp) as seven AI rich motifs. Deletion or manipulation ofthe A
repeats of the packaging signal result in attenuation or loss of packaging of the viral
genome (7). The cystein protease is essential for the maturation and assembly of viral
proteis, and for the release of virions from infected cells ($).At the end of the lytic cycle,
an E3- encoded protein (E3-1 1.6 KDa), called adenoviral death protein (ADP), allows
for efficient release of viral particles by ceil lysis (18).
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1.4 Adenovirus vectors
Adenovirus vectors have become a very popular tool for gene transfer into
mammalian celis (19). They are derived rnainly from the AdV2 and AdV5 serotypes,
because they are well characterized and by contrast to some other serotypes they are
neither associated with severe illness nor tumorigenic in rodents. Adenoviral vectors are
presently considered to be among the most effective viral vectors, based on the foïlowing
properties: a) Ad vectors have a middle size of genome (- 36 Kbp) that are suitable for
the development of large capacity vectors and are stable through successive replication
cycles; b) they are easy to generate and manipulate; e) they show a transducing efficiency
of almost 100% in a variety of animal culture celis; d) They are quite stable and can be
obtained in high titres (e.g., 10h1l012 plaque forming units (PfU)/mfl; e) They are
capable of infecting a broad host range in vitro and in vivo (effective in dividing and
non-dividing or terminally differentiated ceils): f) no significant side effects have been
reported following early clinical application or vaccination with live replicative AdVs; g)
Their genorne rarely integrates into the host chromosome, which is suitable for
applications requiring transient gene expression (20). However, the hybrid adenovirus/
retrovirus or adenovirus! adeno-associated virus vectors can be used to achieve
integration oftransgenes into the genome and long- term gene expression (21;22).
Two types of adenoviral vectors have been used for gene therapy and
vaccination purposes including replication competent and replication defective
adenoviruses. Replication competent AdVs are ideally suited for applications in which
the high level transient expression of transgene is required without the need for the
stability of expression, such as in the case of vaccination. On the other hand, replication
defective adenoviruses are mainly used for protein production and functional studies and
gene therapy purposes. The encapsidation capacity of adenovirus is estimated to be up to
105% of the genome, 2Kbp can be tolerated without deletion (23). The deletion of the
dispensable E3 region (2.7 Kbp) increase the Ad packaging capacity allowing for the
insertion of up to 4.7 Kbp of foreign DNA into the replication- competent AdV.
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Three classes of the defective adenoviral vectors are currently being developed
for gene therapy purposes (see figure 2). First generation adenovirus vectors are made
by substituting an expression cassette for the El and! or F3 region. Since the El products
are necessary for viral growth, they must be provided in trans in specific ceil unes such
as 293 cells, which constitutively express the EYA and E1B genes. Various deletions in
Fi region can accommodate up to 3.2 Kbp and the deletions in F3 region up to 3.1 Kbp
of the foreign DNA. Since adenovirus can package approximateÏy 38 Kb without
affecting growth rate and viral titer (24), E1/E3 deleted viruses allow the cloning of
about 8.2 Kbp. The main advantage ofthe first generation AdVs is that they are easier to
construct and produce than the other classes of defective adenoviral vectors. One
problem for their production is the appearance of replication competent AdV (RCA)
during multiple passages in 293A ceils. The main disadvantage of the first generation
adenovirus vectors is that they elicit a significant immune response in vivo, mainly due
to the synthesis of viral proteins and resuits in a loss of therapeutic gene expression 1 to
2 weeks post infection (25;26). Therefore, additional genes necessary for viral DNA
replication have been deleted, resulting in the second generation of adenovirus vectors.
Different cell unes have been constructed that express the F2a DNA binding protein, the
F2b-encoded terminal protein and viral DNA polymerase, or all or most of the F4
products (27-29). The corresponding deletions should allow a maximum cloning
capacity of 14 Kbp, and show reduced antigenicity in vivo, since they are less
immunogenic. However, the duration of gene expression appears to be reduced. Third
generation AdV is also represented by ‘gutted’ or ‘helper-dependent’ adenoviruses.
These vectors are deleted for all the genes but only remain intact for the cis-acting
sequences including the inverted terminal repeats and the packaging sequences, which
are necessary for viral DNA replication and packaging. Since these gutless vectors are
unable to replicate on their own, the presence of a helper virus (first generation AdV)
and the appropriate complementing ceils for propagation followed by careful purification
are required. In theory such viruses can accomodate the cloning capacity up to 37 Kbp,
however the disadvantage of this approach is due to the difficulty in separating the
gutted vector from the helper virus. A furthcr development involved the use of the Cre
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lox helper-dependent system, which allowed the production of heiper-dependent AdV
reasonably free ofhelper virus (30).
According to their current limitations, adenoviral vectors are flot considered as
the best candidates for treating genetic disorders, which need long- terrn expression of
the therapeutic genes. On the other hand, they may be better candidates in treating
diseases for which only transient gene expression is required such as cancer,
cardiovascular and restenosis.
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Figure 2. Genome structure of first generation, second generation and gutted
adenovirus vectors. The location of the early and late transcription units (arrows) in the
adenovirus genome (black bar) are shown on top ofthe figure. The ITRs are symbolized
by triangles. The packaging signal (‘i’) is highlighted by an open box. Non-adenoviral
sequences in gutless vectors are represented by a thin line. The sizes ofthe largest
deletions are indicated for each region. and the maximal insert sizes are indicated for
each type of vector (30).
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1.4.1 A new replication- competent defective AdV vector
In order to reach the short term high level expression of the transgene a new
replication- competent defective AdV vector has been designed lacking the PS gene. As
previously described the adenoviral PS is one of the essential late viral genes involved in
many steps of the virus cycle. The PS is essential for the maturation and assembly of
viral proteins and for release of virions from infected ceils. By deleting an essential gene
that is flot involved in the early steps of viral replication, it becomes possible to obtain a
localized replication without risk of viral shedding and thus obtain a greatly enhanced
expression of the transgene. The PS deleted virus can be propagated in 293A-derived
cell unes engineered to express P$ (293A-PS) (see Figure 3). Such vectors are suitable
for applications in which over-expression of the transgene such as in the case of
vaccination, in situ therapy for tumors, protein production or the large scale production
of other viral vectors such as adeno-associated virus (AAV).
It has been shown in another application that using a P$-deleted genome and
the ectopic expression of PS gene via transfer vector allowed for positive selection of
recombinant AdVs (31). With this method, since the PS-deleted mutant can flot go
beyond one round of replication in El expressing 293A cells expressing, only those
recombinant genomes having the PS gene can lead to productive infection.
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Figure 3: Replication- competent defective adenoviruses (single- round replication
AdVs). Vectors deleted for PS gene can be completely replicated in complementary ceil
unes. In non-complementary celis, the DNA repticates, and because of the absence of the
PS gene assembly and release of infectious virions could flot occur (8).
1.4.2 Regulatable adenovirus vectors
A rigourous control of gene expression in human gene therapy strategies is
important for both therapeutic and safety reasons. Inducible gene expression is required
to regulate the expression ofthe proteins that are either cytotoxic or which interfere with
Ad replication. Inducible expression cassettes using a chirneric prornoter can be
successfully used for some particular applications in which regulating transgene
expression in vivo improves its safety and/or efficacy.
Since the bacterial tetracycline- regulated system for inducible expression in
mammalian cells (32) is demonstrated as a suitable model, several systems based on
bacterial regulatory elements have been successfully used in AdVs. A number of
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inducible systems either endogenous to mammalian celis or using prokaryotic and insect
regulatory systems are available. In our laboratory a new bacterial operon has been
adapted to regulate gene expression in mammalian ceils (33). In Pseudomonas putida
Fi, the degradative pathway for p-cynzene to its benzoate derivative p-curnate consists of
6 genes organized in an operon (cym) (34). The cym operon is followed by the cmt
operon that is responsible for the future degradation of cumate. The expression of the
genes in both operons is reguÏated by a 28 kDa repressor molecule (CymR) that binds to
the operator sequences downstream of the start site of the promoter. CymR is in a DNA
binding configuration only in the absence of effector molecules including cymene or
cumate. We have used CymR to control gene expression in mammalian ceils with two
different strategies as shown in Figure 4 A and B.
The first strategy is based on using of CymR as a repressor that reversibly
blocks the expression from the strong promoter. The Cumate operator is placed between
the TATA box and the initiation site (19 or 40 bases from the TATA) and is able to
mediate repression by the repressor very effectively. It is possible to regulate DNA
binding of the repressor protein (CymR) from the operon sites. Therefore the expression
of the transgene can be suppressed in the absence of the inducer cumate and induced in
the presence of cumate (A). The second strategy involves in generating a chimeric
cumate transactivator (cTA) by fusing of the bacterial repressor (CymR) to an activation
domain of mammalian celis (VP16). Scince the DNA-binding ability of CymR is
regulated by cumate binding, it is possible to regulate DNA binding of the fusion protein
(CymRVP16) from the operon sites placed downstream ofthe minimal promoter (TATA
box). Therefore the transactivation by the transactivator can be suppressed in the
presence ofthe inducer cumate and induced in the absence ofcumate (B).
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Figure 4: Controling the expression of the transgene via two different strategies of
cumate switch system. A) Repressor configuration, B) Activation configuration (33).
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1.5 Application of adenoviral vectors in gene therapy for cancer
The explanation of the molecular mechanisms underlying neoplastic
transformation bas resulted in understanding that cancer is a genetic disease originating
from the accumulation of a series of acquired genetic lesions. Despite advances in the
traditional treatments of cancer including chemotherapy, radiotherapy and reductive
surgery, cancer remains one of the top causes of death in aduÏt and chiidren. In cases
where the nature of the tumour is more difficuit to treat (e.g., lung and brain cancers) or
where diagnosis is flot possible until very late (e.g., ovarian and pancreatic cancers), the
traditional therapies have proven to be ineffective. Furthermore, traditional treatments
have been videly associated with undesired side effects. It is apparent that novel
therapeutic approaches will be required to obtain significant increases in clinical
survival.
Gene therapy for cancer is a novel approacb with the potential to selectively
eradicate tumour celis while sparing normal ceils from damage. There are several
elements of concem regarding the safety and efficacy for gene therapy of cancer, which
are: a) the target tissue; b) the transgene and its delivery and c) the host response. Among
these factors, gene delivery is a key element. The requirements of an ideal gene delivery
vector for cancer treatment should be evaluated based on the following criteria: a) high
gene-transfer efficacy; b) large gene canying capacity; c) regulation of gene expression;
d) controlled cytotoxicity; e) targeted immunogenicity; f) ease of construction and
manipulation; g) cost-effective production; h) safe and convenient application.
The existing approaches to gene therapy of cancer can be divided into five
broad categories: (1) mutation compensation, (2) molecular chemotherapy, (3) genetic
immunopotentiation, (4) genetic modulation of resistance/ sensitivity, and (5) oncolytic
therapy or virotherapy.
The application of Ad for cancer therapy can be dated back to the 1 950’s, when
wild type adenovirus was used to treat cervical cancer. Ad vector-mediated delivery of
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tumor-suppressor genes, antisense oncogenes, suicide/toxin genes. and other effective
genes have been successfully demonstrated to be effective in inducing tumoricidal
effects and anticancer immunity in different animal models (35;36).
1.5.1 Molecular chemotherapy
A number of well- defined approaches to molecular chemotherapy for cancer
have been developed. These include the administration of (1) toxin genes to eliminate
tumour celis and the stromal celis that support them, (2) drug resistance genes to protect
the bone marrow from myelosuppression induced by chernotherapy, and (3) genes that
enhance the effect of traditional anticancer treatment. Traditional and molecular
chemotherapy follow the same principle, where the pharmacological agents are
employed. However, in the traditional chemotherapy, the toxicity of the drug is ofien
displayed both in malignant and non- malignant celis. Molecular chemotherapy is
designed to selectively target toxin expression to cancer ceils in order to reduce the
potential for non-specific cytotoxicity. In the latest approach, a non- toxic prodrug is
administered and could be transformed into a toxic metabolite only in genetically
modified celis, that ultirnately leads to celi death (37).
1.5.1.1 Gene Directed Enzyme! Prodrug Therapy of Cancer
One of the main goals in anti-tumour therapies is to target toxic agents in a
specific and selective manner to tumour celis, while avoiding the normal cells from
damage. This could be achieved by gene therapy that can specifically perform gene
delivery to the target cells with the specific gene expression in the target celis. The gene
directed enzyme! prodrug therapy (GDEPT) is basically focused on the choice of
therapeutic genes for cancer gene therapy, in particular on molecular chemotherapy or
“suicide” gene therapy. GDEPT is defined as a two step therapeutic approach for cancer
gene therapy. In the first step the transgene is delivered into the tumor and expressed
using potential vectors including adenoviruses and retroviruses. The delivered transgene
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encodedes for an enzyme, which is not toxic by itself. In the second step a non-toxic
compound (prodrug) is administered and is selectively activated and converted to a
potent cytotoxin by the expressed enzyme (38) (see Figure 5). In the choice of the
appropriate enzyme! prodrug combination, priority should be given to the enzyme. For
ease of possible protein modification, the enzyme should be monomeric, of low
molecular weight and with no requirement of glycosylation. It should have high catalytic
activity under physiological conditions, fast and efficient prodrug activation even at Iow
concentrations of the substrate, without dependence on further catalysis by other
enzymes. Expression of the enzyme itself should not lead to cytotoxic effects because
the required bystander effect would not be achieved if the ceils were killed by the action
of the enzyme alone. Several suicide gene! prodrug combinations are currently under
investigation, including cytosine deaminase (CD)!5-fluorocytosine (39), thymidine
phosphotylase/5 ‘-deoxy-5 -fluorouridine (TP/5 -DFUR) (40), purine nucleoside
phosphorylase (PNP)/6- methylpurine-2’-deoxyriboside (MeP-dR) (41) and herpes
simplex virus thymidine kinase type I (HSV-TK) in combination with the prodrug GCV
(42).
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figure 5: Schema of the Gene Directed Enzyme/ Prodrug Therapy via viral vectors.
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1.6 Suicide gene therapy mediated by USV-TK/ GCV system
To date, HSV-TK with the nucleoside analogue GCV is known as the most
well- studied enzyme! prodrug strategy in cancer. Frederic Moolten was the first to
describe the potential of the HSV-TK!GCV system as a prodrug- activating gene
therapy. It was shown that the transfection of tumor ceils with HSV-TK gene makes
these ceils sensitive to GCV. a guanosine analog (42). In fact, in 1990 the initial studies
of HSVTKJGCV gene therapy using retrovirus vectors showed that the expression of
HSV-TK with GCV treatment generated enough phosphorylated GCV to inhibit
mammalian DNA polymerase.
1.6.1 Characterization of the HSV-TK as compared to the mammalian TK
Mammalian thymidine kinase (TK) is a key enzyme in the pyrimidine salvage
pathway phosphorylating to thymidine (dT) to thymidine monophosphate (dTMP) in the
presense of Mg2 and ATP. In the cell, dTMP is subsequently diphosphorylated and
triphosphorylated and finally used as a DNA building block. Moreover, mammalian TK
accepts only pyrimidines, whereas viral 1K from Herpes simplex virus type 1 also
accepts purines. and even the acyclic ribose analogue such as prodrugs acyclovir (ACV)
and gancyclovir (GCV). In virus- infected cells those prodrugs are activated to their
triphosphates and incorporated into the viral DNA resulting in chain termination.
Thymidine kinase belongs to the a/f3 protein family. The core of the protein contains a
parallel 5-stranded f3- sheet and the sheet is surrounded by 12 Œ- helices covering in both
side (43).
1.6.2 Characterization ofthe human Guanylate Kinase (GK)
Guanylate kinase catalyzes the phosphorylation of either GMP to GDP or
dGMP to dGDP and is an essential enzyme in nucleotide metabolism pathway. In
addition to being critical enzyme in the biosynthesis of GTP and dGTP, guanylate kinase
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functions in the recovery of cGMP and is therefore. thought to regulate the supply of
guanine nucleotides to signal transduction pathway components (44;45). Guanylate
kinase activity has been observed in a variety of tissues and has been purified from many
eukaryotic sources including bovine retina, bakers’ yeast, hog brain, rat liver, and human
erythrocytes.
Like the other enzymes involved in nucleotide metaboïism, guanylate kinase is
a target for cancer chemotherapy and is inhibited by the potent antitumour drug, 6-
thioguanine (46). However, guanylate kinase activity is also required for antiviral drug
activity in virus- infected celis. Activation of the anti-herpes guanosine nucleoside
analogs acyclovir and ganciclovir, afier an initial phosphorylation step by the viral
thymidine kinase, is carried out by guanylate kinase. Therefore guanylate kinase is a key
enzyme for cancer chemotherapy and antiviral drug activation in humans.
1.6.3 Mechanism ofthe HSV-TKIGCV system
GCV, an acyclic analog of the natural nucleoside 2’ deoxyguanosine, is an
antiviral agent widely used against human cytomegalovirus, herpes simplex virus type I
and 2, varicella zoster and Epstein-Barr virus. GCV can be converted to its
monophosphate form efficiently by thymidine kinase from HSV-1 (see Figure 6A).
Subsequent reactions catalysed by cellular enzymes including guanylate kinase
(monophosphate to diphosphate) and a number of nonspecific nucleoside
diphosphokinases (diphosphate to trophosphate) (see Figure 6B). GCV- triphosphate
competes with deoxyguanosine triphosphate for incorporation into elongating DNA
during celi division, causing inhibition of the DNA polymerase and single strand breaks.
These characteristics make the HSV-TKJ GCV combination particularly suitable for the
eradication ofrapidly dividing tumour ceils.
In the last 15 years, more than 400 papers have discussed the potentiality of
HSV-TKI GCV for cancer GDEPT. Pre-clinical studies using adeno- and retroviral
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vectors were performed in many different animal models and successful resuits were
reported for established rodent glioblastomas (47;48), rodent liver metastases (49),
human head and neck carcinornas (50), human mesotheliomas (51), murine
hepatocellular carcinomas (52) and other tumour types.
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Figure 6: A) Comparison between ganciclovir (GCV) and nucleoside 2’
deoxyguanosine. B) Metabolic pathway of the prodrug GCV. GCV is specifically
phosphorylated by the herpes simplex virus 1 thymidine kinase (HSV-TK) to its
monophosphate. Subsequently. GCV-monophosphate is converted to the diphosphate
and triphosphate forms by guanylate kinase and other cellular enzymes and can be
incorporated into elongating DNA, causing inhibition of the DNA replication and single
strand breaks (adapted from Fillat et al., 2003).
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1.6.3.1 Mechanisms of HSV-TK/GCV mediated celi killing
The mechanisms of HSV-TKIGCV induced ceil killing is flot completely
understood. There are much evidence showing that both apoptotic and non- apoptotic
pathways have been involved in HSV-TKIGCV mediated tumour killing pathway
depending on the specific ce!! type (53;54). It bas been shown that the apoptotic pathway
is involved in inhibition ofbcl-2 family (55). It lias been shown that the manipulation of
the intracellular levels of bd-2 has been used to divert the mechanism of tumour ce!!
death from apoptotic to predominantly non-appoptotic. By taking advantage of this fact
scientists observed that the non-apoptotic ce!! killing pathway is associated with
induction of heat shock protein (hsp70) expression in vitro and in vivo and also is
invo!ved in increasing the immunogenicity oftumour celis (56).
Several authors have investigated the different HSVtkIGCV- rnediated tumour
killing pathways depending on the specific ceil type. It bas been shown that the
mechanism of ceil death in HSV-TK expressing B 16F 10 murine melanoma ceils is due
to the irreversible ce!! cycle arrest at G2-M checkpoint and is independent of apoptosis
(57). However, it lias been shown that in human hepatocarcinoma celis the HSV/GCV
induces celi death through apoptosis (5$). In this case, tlie level of apoptosis was
dependent on the p53 status of the ce!! being reduced in p53 negative cells compared to
p53 positive celis. In addition, the up-regulation of Fas L was observed in both p53
positive and negative ce!!s but the up-regulation of Fas was observed on!y in p53
positive cells. In contrast, it has been recently shown that in a mode! system of CHO
cells, stab!y transfected with HSV-TK, GCV mediated apoptosis occurs mainly by
activating the mitocliondrial damage pathway independent of p53 status (59).
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1.6.3.2 HSVTKIGCV bystander effect
As explained previously, the HSV-TK system lias been utilized in several
clinical trials in recent years. Despite promising resuits in vitro and in vivo, the anti
tumour effect in clinical trials remains poor. One of the therapeutic limits remains the
low percentage of tumour celis that express the suicide gene after its introduction. An in
vivo transfection efficiency of less than 10% is common and therefore attempts are being
made to increase tliis percentage. However. very higli percentages of transfected ceils are
flot mandatoiy for complete eradication of a tumour in vivo. Transfected tumour celis
appear to be capable of inducing the death of neighboring untransfected celis; this is
called the “bystander effect”. In order to optimize gene therapy, one should also increase
the so-called “bystander effect”. This approacli is based on the observation that not only
the HSV-tk positive ceils (effector celis), but also their neighboring HSV-TK negative
ceils (target cells) are killed after administration of GCV. It was in 1990 that the
bystander effect of the HSV-TKIGCV system was described for the first time. Moolten
and Wells (60) observed that celis transduced with the HSV-TK gene and treated with
GCV induced sensitivity to neighboring non-transduced ceils.
There are different factors that play a role in accomplishing a strong bystander
effect. The primary major limitation ofthe bystander effect in HSV-TK]GCV system lias
been attributed to connexin 43-mediated gap junction intracellular communication,
involving the passage of cytotoxic phosphoryÏated GCV derivatives between the ceils. In
this system the untransfected celis are killed when they receive the GCV-metabolites
through gap junction from neighboring celis. Several studies has sliown that the GCV
mediated ceil killing was enhanced when more celis expressed the HSV-TK gene (61) or
when more copies of HSV-TK is transfected (62), however it was shown that the
increased gap junction communication is needed to enhance the bystander effect and the
therapeutic efficacy (63).
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1.7 Two suicide genes for cancer treatment
An established principle of antineoplastic chemotherapy is that the multidrug
therapies are generaily superior to single agent therapy. The first combined therapy was
based on HSV/GCV and the cytosine deaminase/5-fluorouracil (CD/5-fC) systems. A
cooperative effect of both suicide genes was described in 9L gliocarcoma ceils (64).
Another approach to combine both systems used the CD-TK fusion gene under the
control of a human inducible heat shock protein 70 promoter. A significant reduction in
the survival of prostate carcinoma celis was observed(65). The combination of these two
suicide genes has also been shown to sensitize the tumor celis to radiation (66).
A few studies have referred to the use of CD and uracil phosphoribosyle
transferase (UPRT) for cancer treatment. Two of them have demonstrated that an
adenovirus expressing CD in 9L glioblastoma model extents survival rate of the animais
(67). Another study combining two adenoviruses, one expressing CD and another UPRT
for treating 9L rat glioblastoma, bas shown an increased anti-tumor activity and an
improved survival in rats (6$). A similar study performed in a prostate cancer model has
shown reduction in tumor growth (69).
1.8 Replicating oncolytic adenoviruses
Oncolytic virotherapy is an approach for the treatrnent of cancer, in which the
replicating viruse itself or the genetically engeneered replicative viruses (in case of
adenovirus) specifically target and destroy tumor ceils via their cytolytic replication
cycle. As this approach relies on viral replication, the virus can self-amplify and spread
in the tumor from an initial infection of only a few celis. The success of this approach is
based on the ability to deliver the replication-competent viral genome to target celis (91).
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1.8.1 Oncolytic adenoviruses and gene therapy
Many oncolytic adenovimses have the cloning capacity for a small transgene.
Addition of an auxiliaty therapeutic transgene could augment killing of the infected
tumor celis and the nearby tumor celis via bystander effect. One group of therapeutic
genes that have received much attention in virotherapy is the suicide genes (prodrug
activating genes). In the case of HSV-TK gene the nontoxic prodrug (GCV) could be
converted to its toxic form as previously discussed. The toxic metabolite inhibits the
viral and cellular DNA synthesis and can spread to untransduced tumor cells via gap
junction, thereby enhancing the killing effect beyond the infected ceil (bystander effect).
Targeting gene- virotherapy combines the advantages of gene therapy and viral therapy.
Virotherapy is being re-evaluated based on the findings by Bischoff et aI (70)
demonstrating that the E1B-55KDa-deleted adenovirus (ONYX-015). replicates in and
lyses p53-dysfunctional ceils. This virus that does flot express a therapeutic gene has a
potential to replicate preferentially in tumour celis. It has been used in clinical trials in
patients with advanced carcinoma of head and neck (71). Scientists have combined the
advantages of the prodrug/suicide gene approach with the E1B deficient adenoviral
vector to develop E1B 55 KDa-deficient adenoviral vectors expressing HSV-TK (72) or
canying a cytosine deaminase-HSV-TK fusion gene (73). In Ad-CD/Tkrep that uses a
double-suicide transgene approach, the cytosine deaminase converts 5-fluorocytosine
into 5-fluorouracil, which has antitumor activity. It has been shown that the antiturnor
effect of this virus is enhanced when used in combination with GCV (intravenously) and
5-fluorocytosine (orally) in vivo and in vitro compared with the replicative virus alone or
in combination with a single prodrug (73). furthermore, the addition of radiation therapy
to GCV, 5-fluorocytosine, and virotherapy led to greater tumor growth delay and a 80%
complete response that was superior to other treatment strategy (74). For future vector
developments it will be essential to achieve maximum vector distribution and transgene
expression within tumors and to trigger the immune response against the cancer celis.
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1.9 Goals of this work
A recent publication bas shown that the coexpression of thymidine kinase (1K)
and guanylate kinase (GK) enhances vascular smooth muscle ce!! kil!ing and permits
administration of GCV at lower doses when compared to the expression of thymidine
kinase alone (75).
Based on that pub!ication, we evaluated the cytotoxic effect of the recombinant
adenoviruses coexpressing two suicide genes: TK and GK versus one expressing only the
suicide gene TK. These were tested in two different cancer celi unes inc!uding the human
glioblastoma (U$7) and the ovarian ce!! unes (TOV 21G). We also tested these viruses in
non-cancerous cel!s including normal human fibroblast ce!!s (MRC-5) and human umbilical
vein endothelia! ce!!s (Huvec). The objectives are:
1. Using the coexpression of TK with the GK gene to determine whether the second
phosphoiy!ation of GCV is the rate-!imiting step in tumour ce!!s killing.
2. To determine whether the production of a replication-competent AdV carrying the
above mentioned suicide genes wou!d improve its cytotoxic effect on cancer cells.
3. In the event that replication benefits the activity of the virus, we looked for an
efficient strategy to insert the transgene in the vicinity of the E4 region (between
RITR and E4 promoter) of the adenovirus, in order to have a replication competent
adenovirus for cancer therapy purposes. The objective was to determine the best
configuration for the insertion of the transgene in the region between E4 and RIIR.
This, in order to have the best transactivation of the transgene under the control of a
cumate inducib!e promoter, and the best vira! growth (titer).
Chapter 2:
Material and methods
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2.1 Construction of adenoviral transfer vectors expressing TK or co-expressing TK
and GK
Ail the enzymes used in this study were obtained from New England Biolabs,
Beverly, Mass., USA.
The GfP (Green Fluorsecent Protein) used in the construction of the transfer
vectors is the GfPq of Q-biogen (Q-biogen, Montreal, Canada).
The transfer vector called adenovator that was used in this study consists of two
homology regions with the ieft and right arm of the type 5 adenovirus (Ad5), an origin of
replication (or, a kanamycin resistant gene. The desired genes were cloned in this
backbone in the presence or absence of IRES-GFP. IRES is an internai ribosomal entiy
site that can directly recruit ribosomal 40S subunits for initiation of translation (76).
BamH I
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Figure 7: General map of the adenovator vector.
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2.1.1 AdenoVator-CMV5(CuO)TK-IRES-GfP
The transfer vector pAdenoVator-CMV5(CuO)TK-IRES-GFP was constructed
by ligating the 1K fragment in BglTI- NotI cloning sites of the pAdenoVator—
CMV5(CuO)-IRES-GFP (Q-biogen, Montreal, Canada) transfer vector. The 1K
fragment was generated by PCR from pGT60codAupp (InvivoGen, San Diego), adding
the BglIJ restriction site to the forward primer and the NotI restriction site to the reverse
primer. The PCR amplification was performed with high fidelity Vent enzyme and its
buffer in the presence of DM50 (8% ofthe whole PCR volume).
The PCR reaction was done using the following program:
1- Step 1 96° CI 2 min
2- Step 2 : Cycle 1- Cycle 4 96° CI 45 sec
48° CI 45 sec
72° C1’ 1:30 min
3- Step 3 : Cycle 5- Cycle 25 96° CI 45 sec
65° CI 5 sec
72° C/ 1: 30 min
4- Step 4 72° CI 10 min
5- Step 5 4° C (for conservation)
Then the 1K fragment was isolated by cutting the corresponding 1.3 Kb band from a 1%
agarose gel and purified using the” QIAEX II Agarose Gel Extraction Kit” (Qiagen mc).
Basically, the QIAEX II principle involves the extraction and purification of DNA
fragments based on the solubilization of agarose with chaotropic salt and quantitative
adsorption of nucleic acids to the QIAEX II silica-gel particles. Elution of DNA was
performed in a suitable volume of buffer (eg., TE, pH 8.0, or 10 mm Tris.HC1, pH 8.5).
The purified PCR 1K was cut with the restriction enzymes BglJI and NotI. The transfer
vector pAdenoVator-CMV5(CuO)-IRES-GfP was cut in the multiple cloning sites using
the same restriction enzymes. Then the cutted ends were dephosphorylated with the
aikaline phosphatase enzyme and purified using “QIA quick mini columns” (Qiagen
mc). The purified 1K fragment was ligated into the above mentioned purified transfer
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vector using the 14 DNA ligase enzyme of f. cou and its 14 DNA ligase buffer and
incubated ovemight at 14° C. The ligation reaction product was then transformed into
competent E.coli DH5Œ. Transformation was done by incubating the bacteria and the
DNA for 30 min on ice. Then a heat shock was done at 42° C for 1 mm, and 900 pi of
LB medium was added and the whole reaction was transferred for an incubation of 1 hour
at 37° C in a shaker. The bacteria were then concentrated and spread out on LB agar
plates suppÏemented with 50 jtg/ml of kanamycine. Colonies were picked up, grown
ovemight and analyzed by restriction enzymes. The presence of the 1.3 Kb 1K gene was
confirmed by cutting with BglII and NotI enzymes and verified on 1% agarose gel. Also
the results obtained from PCR with the above- mentioned 1K prirners confirmed the
presence of the 1.3 Kb TK gene. The positive clones were then amplified and the
recombinant DNA was extracted using Qiagen maxi- prep kit (Qiagen mc). Basically,
the QIAGEN plasmid maxi protocol is designed for preparation of up to 500 ng of high
or low- copy plasmid using the QIAGEN plasmid maxi kit. In order to determine the
yield of the extracted recombinant plasmid. DNA concentration was estimated by both
UV spectrophotometiy and quantitative analysis on a 1% agarose gel.
2.1.2 AdenoVator-CMV5(CuO)TK-cite-GK
Ihe TK-cite-GK fragment was isolated from the pBS-TK-cite-GK vector
(Kindly provided by Elizabeth G. Nable, NIH. Bethesda) using the restriction enzymes
)72oI and XbaI and rendered blunt ended with the Klenow fragment of E. cou DNA
Polymerase I. Ihe relation between the 1K and GK was carried out by the cite fragment,
which contains a copy ofthe encephalomyocarditis 5’ noncoding region and functions as
an intemal ribosomal entry site for initiation of translation by eukaryotic ribosomes. The
blunted 2.5 Kb TK-cite-GK insert fragment was purified from a 1% agarose gel as
previousely described. The transfer vector pAdenoVator-CMV5(CuO)mcs (Q-biogen,
Montreal, Canada) was cut in the multiple cloning sites using the restriction enzyme
EcoRV and dephosphorylated and purified. The purified TK-cite-GK fragment was
ligated into the above mentioned purified transfer vector ovemight at room temperature
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and the transformation was performed as previously described. Colonies were picked
and the desired orientation of the TK-cite-GK gene was confirmed by digesting with the
Hind III restriction enzyme and verifying on a 1% agarose gel. Also the orientation ofthe
insert was confirmed by sequencing with the dRhodamine kit (cornpany), using a sense
or an anti-sense oligonucleotides amiealing outside of the multiple cloning site of the
pAdenoVator—CMV5(CuO)-mcs. The following condition were used for the sequencing
reaction:
1 pg of the cloned vector.
0.8 j.il DMSO
(1.6 pmol/ml) of the oligonucleotide
4 d dRod.seq. mix (Amersham Pharmacia biotech, San Francisco, CA)
The PCR reaction was then done using the following program:
1- Step 1 96° CI 10 sec
2- Cycle 1- Cycle 25 96° CI 30 sec
50° CI 5 sec
600 C/4 min
3- Step3 72°C! 10 min
4- Step 4 40 C (for conservation).
Once the reaction completed, the DNA had to be purified on the centri- sep column
(company), and sent for gel analysis (BRI sequencing facility). The sequence obtained
was compared with the expected sequence. Positive clone was then amplified and the
DNA was extracted as previousÏy described.
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2.2 Construction of the adenoviral transfer vectors expressing CR5GFP cassette in
the E4 complete and or E4 deleted orf6 backbones
The transfer vectors named pAd that are used to generate the replicative
adenoviruses are designed in two platforms. In pAdE4-orf6+ext the E4 region of the
adenovirus is deleted except for the orf6 region followed by the polyA site of the
globulin gene but in pAdE4ext the E4 region is flot deleted. Both of the transfer vectors
consist ofa homology region with the right arm ofthe type 5 adenovirus (Ad5), an origin
of replication (on), a resistance gene to ampiciline (13- lactamase), the PacI site in
replacement with the E3 region of adenovirus.
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Figure 8: General map of adenoviral vectors used in this study.
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2.2.1 Construction of pAdCR5GFP-RJPS and pAdCR5GFP-L/PS4
pAdCR5GFP-R/PS and pAdCR5GFP-L/PS were constructed by ligation of
the CR5GfP cassette in $naBI cloning site (165 bp from RJTR) and the PS fragment in
PacI cloning site ofthe pAdE4ext backbone transfer vector. The CR5GfP fragment was
generated by PCR from pAdCR5GFP vector (33), adding the EcoRV restriction site at
both forward and reverse primers. The PCR amplification was performed with high
fidelity Vent enzyme and its buffer.
The PCR reaction was done using the following program:
1- Step 1 96° CI 10 sec
2- Cycle 1- Cycle 4 96° CI 45 sec
48° CI 45 sec
72° CI 1 :30 sec
3- Cycle 5- Cycle 25 96° CI 45 sec
60° CI 5 sec
72° Cl 10 sec
4- Step 4 72° CI 10 min
5- Step 5 4° C (for concervation)
Then the PCR fragment was isolated by cutting the 1.7 Kb band from a 1% agarose gel
and purified as described before. The purified PCR CR5GfP was cut with EcoRV. The
transfer vector pAdE4ext was cut in the SnaBI site using the $naBI restriction enzyme
and dephosphorylated and purified. The purified CR5GFP was ligated into the above
mentioned purified transfer and incubated ovemight at room temperature and the
transformation was performed as described before. The bacteria were then concentrated
and spread out on LB agar plates supplemented with 100 jig/ml of ampiciline. Colonies
were picked up, grown ovemight and analysed by PCR to con±irm the presence of
CR5GfP gene. The sense and antisense orientations of the CR5GfP gene were selected
by cutting with BamHT and CÏaI enzymes verifying on a 1% agarose gel. The positive
clones selected for both orientations of CR5 GfP gene were then amplified and the
recombinant DNA was extracted. The PS gene under the control of 1K promoter
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then sub-cloned into the created PacI site of the constructed vectors. PS fragment was
isolated from the pAdCMV5DCGfP/TK-PS vector (Gagnon et ai, in preparation) using
the restriction enzyme Rad by cutting the corresponding 700 bp band from a 1% agarose
gel and purified. The pAdCR5GfP-R and pAdCR5GFP-L transfer vectors were cut at
the restriction site Rad using the same restricted enzyme and dephosphoryiated and
purified. The purified PS fragment was iigated into the above mentioned purified
transfer vector and incubated overnight at 14° C. The ligation reactions product was
transformed in the competent bacteria as previousely described. Aiso the orientation of
the PS was con±ïrmed by sequencing with the Rhodamine kit, using a sense and or an
anti-sense oiigonucieotides anealing outside of the PacI restriction site of the
pAdCR5GfP-R and pAdCR5GFP-L transfer vectors. The sequencing condition was
performed as explained in 2.1.2 section and the positive clones were then amplifled and
the DNA was extracted.
2.2.2 Construction of pAdCRSGFP-R E4orf6JPS and pAdCR5GfP-L1E4
+ +
orf6 /PS
The transfer vectors pAdCR5GFP-E4orf6/P$ and pAdCR5GfP-L/E4
orf6/PS were constructed by sub-cloning of the PS fragment in Rad cloning site of the
pAd E4orf6 backbone transfer vector at first step and sub-cioning CR5 GfP cassette in
SnaBI cloning site of pAdE4orf6PS transfer vector in both orientations at second step.
PS fragment was cioned in the Rad site of pAd E4orf6ext backbone transfer vector as
described in the previous step. The desired orientation of PS was confirmed by
sequencing. Positive clones were then ampiified and the DNA was extracted. At the next
step, the purified PCR CR5GfP was eut with restriction enzyme EcoRV. hie transfer
vector pAdE4orf6PS was eut at the $naBI site and dephosphoryiated with the aikaline
phosphatase and purified. The purified CR5GfP was ligated into the purified transfer
veetor and incubated ovemight at room temperature. Afier transformation colonies were
picked up, grown ovemight and anaiysed by PCR to confirm the presence of CR5GfP
gene. The sense and antisense orientations of the CR5 GFP gene were selected by eutting
with Notl and FseI enzymes verifying on a 1% agarose gel. The positive clones selected
38
for both orientations of CR5GfP gene were then amplified and the recombinant DNA
was extracted.
2.3 Ccli culture
The human 293A ceil une (77) is the stable fibroblast kidney celi une that
constitutively express Ad5 EIA and E1B genes. Those celis are cultured in DMEM
medium supplemented with 5% FBS serum plus 2 mM L- glutamine. 293A celis were
used for propagation ofthe El deleted recombinant adenoviruses.
The 293ACymR celi fine, a clone derived from 293A celi line, were stably
transfected by pCymR/tk-neo by calcium- phosphate technique as will be described later
and the best clones (clone 21) were selected by infecting with AdCMV5-Cuo-LacZ in
presence and absence of cumate (33). This repressor-expressing ceil une allows the
production of viruses with reduced transgene expression. Those cells were grown in the
same media as described for 293A celis.
The 293A-PS ceil une, a clone derived from 293A cells, expressing the PS gene
was used for generation of PS deleted AdVs. In this attempt, 293A ceils were stably
transfected by pHSE*PSPAV3DCGFPq/tk*Hygro transfer vector by calcium-
phosphate technique and the ceils that were resistant to hygromycin were selected as
positive clones (work done in our laboratory by Castagner.. 2002 unpublished). Those
ceils were grown in the same media as described for 293A cells.
The BMAdEI 78-42 and 220-8 cells are adherent stable ceil lines drived from
the A549 celis expressing the EÏA and EIB genes ofthe Ad5(78). Those ceils are grown
in DMEM medium supplemented with 5% FBS serum plus 2 mM L- glutamine. The 78-
42 ceils were used for purification steps and since they do flot have homology sequences
with adenovims, so they can flot produce the revertants (RCA). They have a low rate of
growth in comparison with 293A ceils, so a higher number of celis should be plated for
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plaque purification in order to have good identifiable plaques (1.5 times celis more than
293A ceils).
The Hela-cIA ceil une, a clone derived from the Hela ceils that stably express
the cumate transactivator cIA. Hela cells were transfected with pcDNA-3cIA
(invitrogene) and selected for G41 $ sensitive (work done in our Ïaboratory, unpublished)
Those celis were grown in the same media as described for 293A ceils.
The glioblastoma ceil unes U87 were obtained from AICC (Manasses, VA),
and grown in the same media as described for 293A celis.
Ihe 10V 21G (kindly provided by Aime-Marie Mes-Masson, Institut du cancer
de Montréal) were derived from epithelial ovarian cancer (EOC) and previously
characterized and shown to mimic features of the tumoral ceils from which they were
derived (79). These ceil unes were grown in the same media as described for 293A celis.
The normal human fibroblast ccli une (MRC-5) was obtained from ATCC
(Manasses, VA), and grown on DMEM supplemented with 10% fetal bovine serum and
2mM L- glutamine. The MRC-5 celis were rinsed with PBS and trypsinised with 0.25%
trypsin instead of 0.05 % and sub cultivated in a ratio of 1:2 to 1:5.
Human Umbilical Vein Endothelial Celis (HUVEC) were kindiy provided by
Maria Moreno (NRC, Ottawa) and their special medium was purchased from Cambrex
Bio Science Waikersvilie Inc. These ceil unes were grown in EGM TM.2MV..
Microvascular Endothelial Celi Medium- 2 supplemented with 5% fetal bovine serum
and growth factors and cytokines. for each 25 cm2 ofHUVEC celis to be subcuitured:
1- The old medium was aspirated
2- The celis were rinsed with 5m1 of room temperature HEPES- BSS in order to remove
ail the proteins of the medium that could be inactivating the trypsin.
3- 2 ml of room temperature Trypsinl EDTA were added to the celis for 2-6 minutes
until approximately 90 % ofthe celis were detached.
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4- 4 ml of room temperature Trypsin Neutralizing Solution were added to inactivate
trypsin.
5- The celis were subcultivated in a ratio of 1 :2 to 1 :5.
2.4 Transfection using Calcium- Phosphate (CaPO4) method
7.5 X ï05 ofthe desired celis were plated in a 60 mm petri dish one day prior to
transfection. The foilowing day the old media was replaced by 2.5 ml of the fresh media
to ascertain that the celis would grow exponentially when they receive the DNA. The
precipitated DNA in 0.IX sterile TE (Tris+ EDTA) was added to a tube and 30 c1 of
CaC12 were added drop by drop to the DNA in TE to have a final volume of 250 i1. In
the second tube 250 1iJ of 2 X HBS (0.2$ M NaC1 + 0.05 M Hepes + 1.5 mM Na2HPO4
PH 7.5) were added and the CaCI2- DNA mix from the first tube was added drop by
drop to the second tube. Then the precipitate was added drop by drop to the medium
covering the celis by trying to cover as much area as possible.
2.5 Virus construction
Ail the recombinant viruses were constructed by the AdEasy method or the
positive selection method as will be described later.
The AdTK-TRES-GfP and AdTK-cite-GK viruses were constructed using the
AdEasy method (Q-biogen) as explained in 2.5.1 section. Ad(PS+)CU-IRES-E1A was
constructed with the AdEasy method by first subcloning of the CU gene in the transfer
vector pAdCMV5-IRES-GfP. At the second step the E1A gene, including its viral
polyA, was inserted in place of GfP downstream of the IRES in order to have co
expression of CD and EYA to have a replicative-dissiminative virus (Bourbeau et al., in
preparation). The AdCR5GfP-L/PS(E3-tk), AdCR5GFP-E4orf6/PS(E3 -tk) and
AdCR5GfP-R/PS were constructed and selected by positive selection method in 293A
cells as explained in 2.5.2 section. The AdCR5GFP-RJPS was constructed by
reinserting the PS fragment in its original space as described in 2.5.3 section. The
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construction of AdCMV5GFP-L/El has been described in details (7$). AdCR5GFP-
L/EF was constructed by in vivo homologous recombination between overlapping
sequences of linearized pAdCR5GFP transfer vector and Ad5/E17E3 (33). Ad PTG3 602
(wild type Ad5) used to generate the Ad5APS and it was amplified in 293-P$ celis (8).
AdE3-E4orf6 was constructed via positive selection by in vivo homologous
recombination between the pAdE4orf6ext transfer vector and Ad5APS virus in 293A
ceils (Elahi et al., in preparation).
2.5.1 AdCMV5(CuO)TK-IRES-GFP and AdCMV5(CuO)TK-cite-GK construction
via AdEasyTM method
The AdEasy method ($0) is a faster way for the production of recombinant
AdVs as compared to the other methods. In this system the viral backbone was made
into a plasmid and is used in place of the linear viral DNA. This permits to perform the
homologous recombination in bacteria instead of the mammalian celis. The viral
backbone (pAdEasy-1) (Q-biogen), which carnes the viral sequences. in these
experiments, is El and E3 deleted. The transfer vectors (pAdenoVator—CMV5(CuO)TK-
IRES-GFP and pAdenoVator—CMV5(CuO)TK-cite-GK were linearized with the
restriction enzyme PmeI, and co-transformed into the E. cou strain BJ5 183 together with
pAdEasy-1. The BJ5183 bacteria cells supplied are electrocompetent and especially
prepared for high transformation and recombination efficiency. The co-transformation
was performed using the electroporation method adding 40 tl of 3J5 183 bacteria ceils
into a 2mm electroporation cuvette following by adding I jig of linearized transfer vector
and 100 ng/pi of pAdEasy-l vector. The transformation was done using an
electroporator supplier at the setting condition of: 5 Ohms, 2.5 KV, C=0. Immediately
afier the transformation mix were resuspended in imi of LB and incubated for ihour at
370 C in a shaker. The reaction mixture was then concentrated and spread out on LB
agar plates supplemented with 50 jig/ml kanamycin. The recombinant plasmids were
selected on kanamycin plates and screened by restriction enzyme analysis with PacI. The
ampiciline resistant pAdEasy-l vectors will flot grow on Kanamycin plates. Then, the
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selected recombinant plasmid was transformed in the competent bacteria, E.coti DH5a,
using the heat shock method as previously described to have high yield of amplification
of the recombinant plasmid. The resulting recombinant adenoviral vectors
(pAdCMV5(CuO)TK-IRES-GFP and pAdCMV5(CuO)TK-cite-GK) were then cleaved
with PacI to linearize the viral DNA and remove plasmid sequences and purified with
Phenol/ChC13 and precipitated with ethanol (Figure 9). Transfection was done with the
calcium- phosphate technique as will be described later into 293 CymR ceils to generate
viral particles. The cytopathic effect of the produced viruses (AdCMV5(CuO)TK-IRES-
GFP and AdCMV5(CuO)TK-cite-GK) on the transfected 293 CymR celis were observed
2-3 weeks post transfection (see fig 9). The lysate mixture were frozen and thawed for
three times to relief the viruses from the celis. To be certain about the purity of the
viruses serial dilutions from 1OE’ to 106, were prepared from the lysate mix in a final
volume of Imi. The serial dilutions were added to the 293A celis prepared the day before
at a density of 5X105 cells/well in 6 well plates. The infection was done at 370 C for 5h
on a rocker. Then the media was removed and celis were overlaid with 1% Sea plaque
agarose in DMEM. Afler 6 days fresh Sea plaque agarose was overlaid on the previous
layer. In 10- 12 days plaques were isolated.
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Figure 9: Production of the recombinant viruses via the Q-biogene Adfasy method.
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2.5.2 Positive selection method for production of recombinant adenoviruses
The positive selection method is based on the fact that the adenoviruses deleted
in the protease (PS) gene (Ad/APS) are capable of only one round of replication in non
complementing ceils including 293A celis (31). This feature was applied for constructing
of the transfer vectors using ectopic expression of PS gene and the schema is shown in
Figure 10.
In order to accomplish the positive selection, PS expressing transfer vectors
were first linearized with FseI restriction enzyme ovemight and purified with
Phenol/ChC13 and precipitated with ethanol. Approximately 7.5 X 1 0 293A celis were
plated in 60-mm dishes the day before transfection. The following day, celis were
infected with the MOI of 0.1 ofAd (APS) virus and incubated at 37°C on a rocker. F ive
hours afier infection, celis were washed, ftesh medium was added and ceils were
transfected with 5 ig of P$ expressing above-mentioned transfer vectors using the
CaPO4 precipitation method, as will described later. The ceils were washed afier
overnight incubation at 37° C and fresh medium was added. Three days later the
transfected- infected mix was collected and frozen and thawed three times. The plaque
purification assay was performed to isolate the recombinant plaques. Serial dilutions
from 10 to 106, were prepared from the transfected- infected mix in a final volume of
imi. The serial dilutions were added to the 293A ceils prepared the day before at a
density of 5X105 cells/well in 6 wells plate. The infection was done at 37° C for 5h on a
rocker. Then the media was removed and ceils were overlaid with 1% Sea plaque
agarose in DMEM. Afier 6 days the fresh Sea plaque agarose was overlaid on the
previous layer. In 10- 12 days the recombinant viruses expressing CR5GFP cassette were
identified.
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Figure 10: positive selection of recombinant AdV by ectopic expression of the PS
gene (31).
2.5.3 Construction of the replicative AdCR5GFP-RJPS+
We constructed the AdCR5GFP-R!PSvirus from the AdCR5GFP-RJPS. In
order to retum the PS fragment to it’s original place, the PAdTG36O2 digested by the
XhoI and NdeI restriction enzymes and isoÏated by cutting the corresponding 5.2 Kbp
band from a 0.7% agarose gel and purified with Phenol/ChC13 and precipitated with
ethanol using the QIAEX II Agarose Gel Extraction Kit”. The 293A ceils were then
infected with the MOI of 0.1 of the AdCR5GfP-RJPS virus and transfected with the
purified insert DNA via calcium- phosphate method. Afeter recombination only the
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293-derived celi llne
Protease
IRES PS
!tion RIghtITR
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AdCR5GFP-RJPS virus could be positively selected and develop plaques on 293A
celis.
2.6 Plaque purification assay
Further purification of the selected plaques was judged necessary for the
isolation of a pure recombinant virus. Each recombinant adenovirus plaque was eluted in
1 ml DMEM, and serial dilutions, from 10 to 106 was used to transduce 5X103 of the
desired celis in a final volume of lml in 6 well plates. The infection was done at 370 C
for 5h on a rocker. Then the media was removed and celis were overlaid with 1% Sea
plaque agarose in DMEM. After 6 days ftesh Sea plaque agarose was added. In 10 to 12
days, plaques appeared and were picked and analyzed. In our experiments 293CymR
celis were used to purify the AdCMV5(CuO)TK-IRES-GFP and AdCMV5(CuO)TK-
Cite-GK. However, the 293A celis were used to purify ah the replicative and non
replicative CR5GFP/PS expressing viruses and the 293-PS ceils were used for
purification of AdCR5GfP-RIPS virus. for ail the non-replicative recombinant viruses,
plaque purification was repeated on BMAdE1 78-42 ceils as a resuit of the presence of
the RCA in the viral population. 7.5 X105 BMAdEY 78-42 cells/well in 6 well plates
were transduced as described above.
2.7 Vira] production from the purified p]aques
The amplification of the AdTK-IRE$-GfPq and AdTK-Cite-GK viruses was
done on 293CymR cehis. Whereas the amplification ofAdCR5GFP-PJPS, AdCR5GfP-
L/PS(E3 -tk), AdCR5GFP-E4orf6/PS(E3 -tk) and AdCMV5 GFP-L was performed
on 293A celis and the AdCR5GfP-R/PS on 293-PS celis. Five hundred microliters of
the elutes was used to infect 5 X l0 celis in a 60-mm plate in 1.5m1 and on a rocker for
5h at 370 C. Then media was added to have a final volume of 3ml and kept at 37° C.
Once all the ceils were detached, they were frozen and thawed three times, SO the viruses
can be released from the ceils. One milliliter of this cell lysate was added to 2.5 X 106
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cells in a 100-mm plate with 3 ml of the media on a rocker for 5h at 370 C, and then
media was added to a final volume of 10 ml. The celis were gathered as previously
described and finally amplified in a 150-mm plate containing 5 to 7 X 106 ceils infected
with 3 ml of the ccli lysate and 5 ml of media on a rocker for 5h at 370 C and media was
added to have a final volume of 15 ml. The detached cells were frozen and thawed for 3
times centrifuged at 3000 rpm for 5min and concentrated in 10 ml media and were used
as a final stock for titration.
2.8 Titration of the adenovirus vectors
A virus titer is an expression of the number of infectious units per unit volume
and it can be determined by different methods. The plaque assay method is the most
popular method and is considered the standard but more time consuming method for
viral titration. The Tissue Culture Infectious Dose50% (TCID50) method is faster, easier
and less expensive but less accurate than the plaque assay method.
The titration of AdCMV5(CuO)TK-IRES-GFP and AdCMV5(CuO)TK-cite
GK viruses was performed by using the plaque assay method. This rnethod is based on
the infection of the desired cells with serial dilutions ranging from 10 to 1OE1° of the
final stock of the virus (the final amplification step). 293 CymR ceils were plated at a
density of 5 X I cells per 60 mm dish the day before infection. The next day, cells
were infected with 500 tl of the prepared dilutions for 16 h to have maximal adsorption
with agitation at 37° C. from the i0 to i0 dilutions the cells also were infected with
300 pi and 200 pi in order to have better isolated plaques and a more precise estimation
of viral titer. The day afier infection the medium was removed from the ceils and
replaced by 5 ml of 1% sea plaque agarose in DMEM. Afier one week the cells were
overlaid with extra 3 ml of 1% sea plaque agarose in DMEM. After two weeks post
infection dishes that have less than 100 plaques were chosen and counted with unaided
eye and titers were obtained using the following formula:
4$
Average number of the plaques
PfU
/ ml
Volume of infection X dilution
PFU is the number of plaque- forming units per milliliter of original suspension.
The titration of the recombinant replicative and non-replicative viruses
expressing CR5GfP cassette ftom a region between RITR and E4 and control replicative
and first generation viruses used in this study were performed using the TCID50 method.
In this method the desired cells (293A) cells were plated at a density of 1.2 x celis in
96 wells plates. The day afier media was removed and infected with 50 tl of the serial
dilutions ofthe desired virus ranging from ÎOE’ to 1OE1° ofthe final stock ofthe virus (the
final amplification step). The 8 wells of each row were infected with the same dilution
stock and the row 11 and 12 were uninfected for the negative control. The infection was
done at 370 C for 5h on a rocker and then fresh media were added to each well. The
plates were lefi at 370 C for 10 days. Afier 10 days the number of wells including the
green cells were counted in each row using the fluorescent microscope.
In order to calculate the titer the ratio of positive wells per row was calculated using the
KARBER method (Manual Adeno-QuestT1 version 01DE98):
For 100 jil of dilution, the titre is T = 10 1 + d (S - 05)
1 d = Log ‘° ofthe dilution ( = I for a ten-fold dilution)
2 S the sum ofthe ratios
For lml of dilution, the titer is T = 10 [1 + d (S - 0.5)] + 1 TCID50 / ml
It has been shown in several studies that PFU detection is less sensitive than TCID50
assay (92; 93). The difference is due to the longer period of direct contact between the
ceils and the virus medium in TCID50 assay. However, in plaque assay method the virus
medium is removed afler about 16h and is replaced by agarose.
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2.9 Extraction of adenovïral genome (by HIRT extraction method)
The HIRT extraction is a method of extracting the small extra chromosomal
DNA in the ccli such as viral DNA or Plasmid (94).
293A or 293 CymR ceils were plated at a density of 2.5 X iû celÏs per 12 wells dish the
day before infection. The next day celis were infected with 300 pi of eluted plaques or
100 pi of the amplifted stock and kept at 370 C. Once ail celÏs were infected and
detached, they were collected to an eppendorf and washed once with PBS and
centrifuged in a micro centrifuge at 3000 rpm for 3 minutes. The pellet was then re
suspended in 250 pi of TE and the lysis buffer were added to the mixture and incubated
at 370 C for 2 hours:
SDS 0.6%final
EDTA 10 mM final
Proteinase K 200 j.tgr/ml final
At the next step the suitable volume of NaCl 5M were added to have a final
concentration of 1M in order to precipitate the cellular genornic DNA. The mixture were
incubated on ice for at least 2 hours and centrifuged in a micro centrifuge at 13000 rpm
for 30 minutes. The supematant containing the viral genomic DNA were isolated
carefully and purified with Phenol. Phenol/ChC13 and ChC13 at the equal volumes and
precipitated with 100 % and 70 % ethanol. The precipitated viral DNA was then re
suspended in sterile water or TE.
2.10 Western blotting
This method was used to verify the expression of the proteins from the
constructed recombinant adenoviruses.
Two days afier infecting celis with the suitable recombinant adenoviruses, ceils were
collected and washed twice with PBS and centrifuged in a micro centrifuge at 5000 rpm
for 3 minutes. The pellet was then re- suspended in 250 pi of Laemmli buffer (10 mM
50
Tris- HCÏ, pH 7.4, + 150 mM NaCJ, 1% triton x-100, 0.25% SDS, 1 mM EDTA) and
sonicated to shear the chromosomal DNA and to overcome the viscosity. The protein
samples were then dosed using the DC Protein Assay micro plate protocol from Bio-
Rad laboratories (Hercules, CA). The absorbency was read using a micro plate reader
from Dynatech MR 5000 at a wavelength of 590 nm. The samples were diluted with
Laemmli reducing 2x buffer (120 mM Tris- HC1, PH 6.$, 4% SDS, 20% glycerol, 10%
mercaptoethanol, 0.01% BromophenoÏ BÏue) to have 0.5- 1 tg total protein. Diluted
samples were heated at 95° C for 3- 4 minutes and loaded onto a sodium dodecyl sulfate
polyacrylamide gel electrophoresis (SDS- PAGE) 10- 14% gel acrylamide Tris- glycine
gels (NOVEX) that were run using 125 volt for 3 hours. following electrophoresis, gels
were transferred onto nitrocellulose Trans- Blot membrane (Bio- Rad Laboratories,
Richmond, CA) at a 275 mA for one hour. The transfer buffer consisted of 25 mM Tris
HC1, 192 mM glycine and 25%, of the final volume, ethanol. The non- specific sites
were then blocked by incubating the membrane in a solution of 4% nonfat dry milk
(Nestle, Don Mills, Ontario) in TBS (100 mM Tris- HC1, pH 7.5 + 9.9% NaCI) with
0.1% Tween 20 ovemight at 4° C on a rocker for TK protein and 2 hours at room
temperature for GK protein. The membrane was then incubated with the primary
antibody using the recommended dilution. TK antibody (kindly provided by William C.
Summers, Yale university) was used in a dilution of 1/1000 and incubated for 2- 3 hours
in a solution of 3 ml TBS- Tween 20 at room temperature using a rocker and GK
antibody (purchased from Nordic inirnunological labratories) was used in a dilution 1/50
and incubated ovemight in a blocking solution (9m! TBS- Tween 20 + I ml 5% milk).
The membrane was then washed (3x lOmin) with TB$- Tween 20. The membrane was
then incubated with second antibodies; HRP-coupled anti rabbit serum diluted 4/10000
for TK and GK proteins, for one hour at room temperature using a rocker. The
membrane was then washed, as mentioned earlier, and the signals were detected using
the ECL chimioluminescent detection kit (Amresharn Pharmacia biotech, San Francisco,
CA). It is a light emitting non- radioactive method for detection of immobilized specific
antigenes, directly or indirectly with horseradish peroxide (HRP) labeled antibodies.
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Kodak BIOMAX MR films (Eastem Kodak Rochester, NY) were used to register the
signais.
2.11 Binary dilution ofthe prodrug (DDD)
Ceils were plated at a density of 5X103 per well in 96 weii plates. The following
day, celis were transduced with the appropriate multiplicity of infection (MOI) in 50 .d
for 4-5h, and binary dilution of GCV starting at 8.3 or 83.3 tM (depending on the celi
une) were added (50 cl). Cells were incubated for 6 days and analysed by MTT [3-(4.5-
dimethylthiazol-2-yl)-2 . 5-diphenyl tetrazolium bromide] (Sigma, Oakville, Canada)
assays. Each condition was performed with 8 replicates and each experiment was done
twice. The concentration of GCV was demonstrated in tg/mi in ail the figures and was
calculated using the MW ofGCV (255.5 g) to convert the 1.iM to jrg/ml.
2.12 Bystander assay
Celis were plated at a density of 2 X105 in 12 weli plates. The following day,
they were transduced with the appropriate vector at the proper MOI. Afier 5h transduced
celis were trypsinized and resuspended in 2 ml of media. Doubling dilution of
transduced cells were prepared and added on to 96 well plates in 50 pi. The non
transduced cells (bystander cells) were trypsinised and diluted to have 2 Xl 0 cells/ml,
and added to the wells with transduced celis in 50 pi. The non-transduced dilutions were
prepared with or without GCV at the appropriate concentration. The ratios of the
transduced ceils are as following: 50%, 33%, 20%, 11%, 6%, 3%, 1.5%, 0.8%, 0.4%,
0.2%. The celis were incubated for 6 days and analyzed by MIT assay. Each condition
was performed with $ replicates and each experiment was done twice.
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2.13 MIT assay
Ceils were incubated with colorometric MTT [3 -(4,5-dimethylthiazol-2-yl)-2 .5 -
diphenyl tetrazolium bromide](Sigma, Oakville, Canada) at a final concentration of 1
mg/ml for 4h. The medium was removed and replaced by DMSO. Optical density was
measured at 490 nm. Ceil viability is proportional to the absorbance at the test
wavelength (490 nm). MTT assay measures the number of living cells and is an indirect
measurement of celi killing.
2.14 Guanylate kinase enzymatic assay
The guanylate kinase enzymatic assay involves the indirect measurement of
both ATP and GDP formed from ATP and GMP by coupling the above reaction to the
pymvate kinase and lactate dehydrogenase reaction. The decrease in absorbancy or
increasing in transmittance (transferring the light through the sample) at 340 nm
associated with the NADH oxidation and is measured with a spectrophotometer using a
blue filter ($1).
ATP + GMP ADP+ GDP
ADP, GDP +2 PEP ATP. GTP +2 Pyruvate
2 Pyruvate +2 NADH +2 H 2 lactate +2 NAD
2.5 x 106 293A and HeLa ceils were plated in lOOmrn dishes. The CeÏls were
infected with AdV CMV5(CuO)TK-IRES-GFP and AdVCMV5(CuO)TK-Cite-GK at
MOI of 10 for 293A cells and MOI of 20 for Hela celis. The 293A ceils were collected
28-29 hours, but the Hela celis were coHected afier 48 hours post- infection. The
collected ceils were washed twice with P35 and centrifuged in a micro centrifuge at
5000 rpm for 3 minutes. The pellet was then re- suspended in 500 pi of the following
solution buffer (0.1 M Tris-HC1 buffer + 0.1 M KC1 + 0.01 M MgCÏ2).
fmal concentration
Stock Solutions (1 ml reaction volume)
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1. Tris- HC1 buffer, 1M, pH 7.5 0.1 M
2. KC1, 1M 0.1 M
3. MgCÏ2,0.1 M 0.01 M
4. Sodium Phosphoenol Pyruvate, 15 mM 1.5 mM
5. Pyruvate Kinase, 25 units/ml 2.5 units
6. Lactate dehydrogenase, 33 units/ml 3.3 units
7. NADH,L5mM 0.l5mM
8. ATP. 40 mM 4 mM
9. GMP, 1 mM 0.1 mM
With the exclusion of GMP, equal volumes of the rest of the above mentioned
reagents were added to form a GMP kinase reaction mixture (GKRM). 0.8 ml of GKRM
was pipetted into irni cuvette and the transmittance were recorded at 340 nm. At the
time when the transmittance (1340) reading was being unchanged, the extracted sample
solutions (0.1 ml) was added to the cuvette containing GKRM and the rate of change for
(T340) was recorded every 20 seconds for 5 minutes at room temperature. Any
contaminating enzymes that may degrade ATP, PEP, or NADH resuit in a constant rate
of decrease in A340 absorbance or the increasing rate in (T340), which represents a
background rate. Afier having a steady background, 0.1 ml GMP (1 mM) were added to
the cuvette to initiate the guanylate kinase reaction. The difference between the
increasing rate of (1340) after adding GMP and the background rate represents the rate of
guanylate kinase activity expressed as T34o per minute.
2.15 FIow Cytometry analysis
flowcytometry analysis for GFP expression was performed on a Coulter 1M XL-
MCL flow cytometer (Beckman-Coulter, F) equipped with 15mW at 482nm argon ion
laser as an excitation source. The green fluorescence emission was detected using a 550
nm dichronic long pass and a 525 nm band pass filter set. 10,000 celis gated on forward
and side scattering were analyzed per sample. Transduced celis were transferred into a
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special tube for flowcyton;etry and 0.2 ml of 10% paraformaldehyde were added to the
samples and incubated for 30 min at room temperature. The samples were filtered and
analyzed for the expression of GfP.
Chapter 3:
Resuits
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3.1 Construction of pAdCMV5(CuO)TK-IRES-GFP and pAdCMV5(CuO)TK-cite-
GK transfer vectors
Construction of the pAdCMV5(CuO)TK-IRES-GFP and pAdCMV5(CuO)TK-
cite-GK transfer vectors was done using the AdEasy method as described in detail in
material and methods (see 2.5.1). The construction of these recombinant AdVs was a
two step process, in which the desired expression cassette is first assembÏed into an
adenovator transfer vector, and subsequently transferred into the supercoiled adenoviral
genome (pAdEasy-) by in vivo homologous recombination in bacteria. The wild type
adenovirus has been modified to produce the AdEasy-1 recombinant virus vector.
Regions of the viral genome has been deleted (AE 1, AE3) to prevent the lytic infection
and also to make space for foreign DNA since a maximum of 38 Kb can be
encapsidated. Schema of the transfer vectors are shown in Figure 11.
TK
kan kan
Cri
RITR
LITR
GK
pAd-CMV5(CuO)TK-cite-GK
cite
Ad5E1iE3
Figure 11: Schema of the transfer vectors used in this study.
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3.1.1 Evaluation of cytotoxic activity of 293A celis transfected with
pAdCMV5(CuO)IK-IRES-GFP and pAdCMV5(CuO)IK-cite-GK
At the first step before construction of the recombinant viruses the expression
of TK protein and the cytotoxic activity of our suicide genes from pAdCMV5(CuO)TK-
IRES-GFP and pAdCMV5(CuO)IK-cite-GK transfer vectors were evaluated using a
bystander assay. For western blotting two different protein loadings (1 and 2 tg) were
used to ascertain that the blots were flot saturated and that quantification and comparison
were sufficiently reliable. Ihe resuits of western blot showed that the level of 1K
expression from both transfer vectors as almost the same with slightly higher level of
expression from pAdCMV5(CuO)TK-IRES-GfP transfer vector (figure 12). The higher
TK expression from pAdCMV5(CuO)TK-IRES-GfP could be due to the difference in
the number of transfected ceils (transfected with pAdCMV5(CuO)1K-IRES-GfP and or
pAdCMV5(CuO)TK-cite-GK transfer vectors), that could occur by transfection method.
At the next step the bystander assay was performed to determine whether our genes are
functional or flot and to get an idea about the difference in the cytotoxic activity of 1K
alone as compared to the co-expression of 1K and GK in presence of GCV.
The bystander activity was assessed in 293A celis by mixing the transfected
ceils (transfected with pAdCMV5(CuO)TK-IRE$-GFP and or pAdCMV5(CuO)TK-cite-
GK transfer vectors) with non-transfected ceils. The resuits of the bystander activity
using different concentrations of GCV showed that our suicide genes are perfectly active
but did not demonstrate any difference in cytotoxic activity between two transfer vectors
carrying TK-cite-GK and TK-IRES-GFP cassettes (Figure 1 3A). In comparison between
the 1C50 (the required percentage of transfected celis to kiil the 50% of celis) of the
above mentioned transfer vectors, we have demonstrated that almost the same amount of
transduced celis were required (Figure 133). Ihese resuits showed that the co-expression
of a second suicide gene (GK) with TK gene bas no improvernent in cytotoxic effect
with the transient transfection. In order to get more solid results for better conclusion, the
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next step would be the construction of the AdTK-IRES-GfP and AdTK-cite-GK viruses
from the transfer vectors and the cytotoxic activity of the viruses would be evaluated.
(1tg) (2tg) (1tg) (2ig)
KDa 1 2 3 4
1, 2: 293A ceils I pAdCMV5(CuO)TK-IRES-GFP
3, 4: 293A celis / pAdCMV5(CuO)TK-cite-GK
I: Transfected by
Figure 12: Comparison of the expression of the TK protein in the 293A ceils
transfected with pAdCMV5(CuO)TK-IRES-GFP (lane 1 and 2) and
pAdCMV5(CuO)TK-cite-GK (lane 3 and 4). The expression of the TK protein was
evaluated by western blot 42h after transfection. Each sample was loaded twice on the
gel 1 jig and 2ig of total protein on a 12% denaturing SDS-PAGE gel. Western blot
analysis was perforrned by standard rnethods using a 1/1000 dilution of the polyclonal
rabbit anti-H$V-1 TK antibody. The 1/2500 dilution of the HRP-coupled anti rabbit
serum were used as a second antibody.
40 +
.- —
59
A
B
100%
>
4-
50%
>
0%
293A
%transfected ceNs
Figure 13: Comparison of the bystander activity of the transfected 293A ceils with
pAdCMV5(CuO)TK-IRES-GFP and pAdCMV5(CuO)TK-cite-GK transfer
vectors. Celis were transfected with respective pAdCMV5(CuO)TK-IRES-GfP and
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pAdCMV5(CuO)TK-cite-GK using the calcium- phosphate method. The transfected
ceils were mixed with the non- transfected celis at 24h post transfection at different
ratios. The ratio oftransfected celis was as following: 100%, 50%, 33%, 11%, and 0%.
Then GCV were added at concentration of 2 .ig/m1. GCV were flot added to the controls
using the exact ratio of transduced ceils. Ceils were incubated for 6 days and ceil
proliferation were measured using a colorimetric MTT assay. Each condition was
performed with 2 replicates and the data were presented as means of two replicates plus
the standard deviation. A) Curves obtained from the mean of 293A cells. B) Comparison
between the ratio ofthe transfected cells to reach the 1C50.
3.2 Construction of the recombinant AdVs expressing TK and co-expressing TK
and GK
We have constructed two AdVs for use in cancer therapy. In order to construct
these viruses, the pAdCMV5(CuO)TK-IRES-GFP and pAdCMV5(CuO)TK-cite-GK
transfer vectors were linearized and 293 CymR expressing ceils were transfected as
described in material and methods (see 2.5.1). In our attempt to isolate the recombinant
viruses in 293- CymR ccli une, the co-expression of the GfP with the TK gene in the
AdTK-IRES-GfP facilitated the selection of the recombinant virus plaques. The plaques
were easily identified by fluorescent microscopy as green plaques on the monolayer
culture that was overlaid with agarose. Then the individual plaques were analyzed by
PCR of the extracted viral genome (extracted by HIRT method) for the gene of interest
(1K) and the expression of the TK gene was demonstrated by western blotting (resuits
not shown). In the case of the AdTK-cite-GK there was no GfP co-expression, so few
white plaques were picked and eiuted in 1 ml media. Hence, the eiuted plaques were
analyzed for the presence ofthe TK and GK genes by PCR on the extracted virai genome
and demonstrating their expression by western blotting (results flot shown). f inally the
AUTK-IRES-GFP and AdTK-cite-GK viruses were purified, ampÏified and titered.
A schema of the AdVs is presented in figure 14. Those first generation AdVs
have deietions in El and E3 regions. The cassettes were introduced in the El region with
an anti-parallel orientation with E 1. In these viruses the expression of the transgenes
from a dicistronic cassette is controlled by the CMV5(CuO) inducible promoter. In this
promoter, the CuO operator sequence was placed 19 base pairs downstream of the
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TATA box (between the TATA box and the initiation site). In this strategy CymR is
used as a repressor that reversibly blocks the expression of the transgene from a strong
promoter with the CuO operator. The CMV5(CuO) regulatory promoter allows the
repression of the transcription of cytotoxic gene during AdV production in 293 celi lunes
expressing CymR repressor.
First generation / AUTK-IRES-G FP
1K
First generation I AU TK-Cite-GK
GK 1K
Cite CMV5 (CuO)
t)) Li))
Left E1
ITR
Figure 14: Schema of the first generation recombinant adenovirus vectors AdTK
IRES-GFP and AdTK-cite-GK.
3.2.1 Assessment of the recombïnant AdV genotypes
In order to verify that both of the AdVs population used in this study were
properly designed, PCR was carried out to test for the presence ofthe 1.3 Kb TK gene in
AdTK-IRES-GFP and AdTK-cite-GK afier being purified and arnplified. The
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pGl6OcodAupp vector was used as positive control for 1K gene (figure 15A). Ihe
presence of the 593 bp GK gene in AdTK-cite-GK was also tested by PCR. The
pAdCMV5(CuO)IRES-GFP vector was used as a negative control and pBS-IK-cite-GK
vector was used as a positive control for GK gene (Figure 153). The presence of E1
revertants (RCA) were tested by PCR for E1A region and the resuits were negative for
both viruses (resuits not shown).
1 2 3A
1.3 Kb-*
B
1: ctr(+)pGT6OcodAupp
2 : AdTK-IRES-GFP
3 : AdTK-cite-GK
1 2 3 4
593 bp*
1: AdTK-cite-GK
2: AdTK-IRES-GFP
3: ctr(-) pAdCMV5(CuO)IRES-GFP
4: ctr(+)pBSTK-cite-GK
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Figure 15: Adenoviruses genotypic characterization. 293A cells were transduced with
AdTK-IRES-GFP and AdTK-cite-GK and the genomic viral DNA were extracted using
the HIRI method. A) Genomes were tested by PCR for the presence ofthe 1K gene. B)
For the presence of GK gene.
3.2.2 Assessment of TK and GK expression from the recombinant AdVs
The TK expression ftom the AdIK-IRES-GfP and AdTK-cite-GK viruses was
evaluated via western blotting and it was well expressed (resuits flot shown). The
expresssion of the GK gene was also evaluated by western blotting for GK protein
(Firnre 16). Ihe AdIK-IRES-GfP was used as a negative control.
1 2 3 KDa
.
1
1: mock (non-infected)
2: AdTK-IRES-GFP
3: AdTK-cite-GK
Figure 16: Evaluation of the expression of the GK protein in the 293A ceils. 293A
celis were transduced with AdTK-IRES-GfP and AdIK-cite-GK at the MOI of 10. The
expression of GK protein was evaluated by western blot 48h post transduction. 10 ig of
each sample was loaded of total protein on a 10% denaturing SDS-PAGE gel. Western
blot analysis was performed by standard methods using a 1/50 dilution ofthe polyclonal
rabbit anti GK antibody. A 1/2000 dilution of the HRP-coupled anti rabbit sernm was
used as a second antibody.
3.3 Cytotoxic activity
b characterize the anti-tumor activity of AdTK-IRES-GFP and AdTK-cite-GK
viruses, we determined the GCV concentration required for our above mentioned AdVs
to kiil the glioblastoma U$7 and ovarian cancer ceils 10V2 1G. Then we determined the
cytotoxic activity of the AdVs on non-cancerous cell lines including the normal
fibroblast cdl unes (MRC-5) and human umbilical vein endothelial cells (Huvec cells).
In order to have a quantitative comparison of the vectors in ail the experiments we
looked for the doses of GCV that resulted in a 50% reduction in viability tIC50).
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The titer of the AdTK-IRES-GFP and AdTK-cite-GK viruses was determined
in 293 ICymR ceils under the same condition as explained in section 2.8 of material and
methods and was 1 PFU/ml and 8 x 108 PFU/ml respectively.
3.3.1 Cytotoxic activity of AdTK4RES-GFP and AdTK-cite-GK in U$7 celis
In order to charactesrise the anti-tumour activity of AdTK-IRES-GFP and
AdTK-cite-GK viruses in U87 celis, the ceils were transduced with the respective AdVs
at MOI of 20. Subsequently a set ofbinary dilutions ofthe prodrug GCV starting from 2
tg/m1 to 0.004 tg/m1, were added to the ceils. In U87 ceils, we found that the cytotoxic
activity ftom both viruses were similar albeit a slightly higher activity for AdTK-IRE$
GFP (Figure 1 7A). We have determined that the 1C50 of AdTK-IRES-GFP was 2.7-fold
higher than AdTK-cite-GK (Figure 173). The resuits demonstrated that co-expression of
the GK gene with TK has no superior cytotoxic activity in U87 ceils.
A
100%
• 50%
0%
U87
0 0.1 0.2 0.3 0.4 0.5
0CV ( pglml)
-
- ctr (-virus, + Drug) • AUTK-IRES-GFP L AdTK-Cite-GK
65
B
U87
025
0,2
o
0,15
E
>
0,1
0,05
Figure 17: Comparison of antitumor activity of AdTK-IRES-GFP and AdTK-cite
GK in U87 ceils. Celis were transduced with the respective AdVs at a MOI of 20.
Subsequently a set of binaiy dilutions of the prodrug GCV starting from 2 igIml to
0.004 jig/ml, were added to the celis. As control, non-transduced celis were also treated
with the same binary dilutions of GCV. Celis were incubated for 6 days and celi
proliferation was measured using the colorimetric MTT assay. Each condition was
performed with 8 replicates and each experirnent was repeated twice and the data were
presented as means of two experirnents plus the standard deviation. A) Curves obtained
with the mean ofU$7 ceils. B) Comparision ofIC50 at MOI of 20 for both viruses.
3.3.2 Cytotoxic activity of AdTK-IRES-GFP and AdTK-cite-GK in TOV-21G cel]s
In this experiment, in order to characterise the anti-tumour activity of AdIK
IRE$-GFP and AdIK-cite-GK viruses in 10V 21G celis, the ceils were transduced with
MOI of 20. Subsequently a set of binary dilutions of the prodrug GCV at the same
concentration as U87 celis starting from 2 jig/ml to 0.004 jtg/ml, were added to the ceils.
The resuits showed that the cytotoxic activity using different concentration of GCV was
similar with the two viruses albeit a slightly higher cytotoxic activity for AdTK-IRES
GFP (Figure I 8A). The results of the 1C50 showed a 1 .5-fold higher cytotoxic activity for
o
AdTR-IRES-GFP AdTK-Cite-GK
AdTK-IRES-GFP compared to the AdTK-cite-GK virus (Figure 1 8B). The results of the
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cytotoxic assay in TOV21G ceils showed the same resuits as in U$7 ceils. In TOV2IG
celis the co-expression ofthe GK gene with 1K has no superior cytotoxic activity.
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Figure 18: Comparison of antitumor activity of AdTK-IRES-GFP and AdTK-cite
GK on TOV21G celis. Ceils were transduced with the respective AdV at a MOI of 20.
Subsequently a set of binary dilutions of the prodrug GCV starting from 2 ig/m1 to
0.004 jig/ml, were added to the ceils. As control, non-transduced celis were treated with
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50%
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AdTK-IRES-GFP AdTK-Cte-GK
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the same binary dilution of GCV. Ceils were incubated for 6 days and celi viability was
measured using the colorometric MIT assay. Each condition was performed with $
replicates and each experiment was repeated two times and the data were presented as
means oftwo experiments plus the standard deviation. A) Viability curves obtained with
the mean of 10V 21G ceils. B) Comparison of 1C50 at MOI of 20 for both viruses.
3.3.3 Cytotoxic activity of AdTK-IRES-GFP and AdTK-cite-GK on MRC-5 ceils
In order to confirm the obtained resuits of the cytotoxic effect of AdTK-IRES
GfP and AdTK-cite-GK viruses in cancerous celi unes their cytotoxic effect was
evaluated also in non-cancerous cell unes including MRC-5. The non-cancerous human
fibroblast celis (MRC-5) has been derived from normal lung tissue of a 14-week-old
male fetus by J. P. Jacobs in September 1966 (Nature 227. 168-170, 1970) and is
suceptible to a wide range of human viruses and supports the growth of mai ority of
human viruses including adenoviruses. In this experiment the cells were transduced with
MOI of 50. Subsequently a set of doubling dilutions of GCV starting from 20 .ig/ml to
0.04 jtg/ml, were added to the celis. Compared to the U$7 and 10V 21G cell lines these
ceils were more resistant for viral infection and MOI of 50 was detected as the best MOI
for evaluation of TC50 in MRC-5 celis. However, these cells were more resistance to
GCV and the test was managed with the binary dilution of GCV starting with 1 0-fold
higher concentration of GCV compared to U87 and 10V 21G cells.
The results demonstrated that in MRC-5 ceils the cytotoxic activity of AdTK
IRES-GfP and AdTK-cite-GK viruses using different concentration of GCV did flot
show a remarkable difference (figure 19 A and B). The resuits demonstrated that co
expression of the GK gene with TK has no superior benefit for viral cytotoxic activity in
the non-cancerous MRC-5 cell line.
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Figure 19: Comparison of the viability of the non-cancerous celis, MRC-5, transduced
with AdTK-IRES-GFP and AdTK-cite-GK viruses. Celis were transduced with the
respective AdVs at a MOI of 50. Subsequently a set of doubling dilutions of GCV
starting from 20 tg/ml to 0.04 jig/ml, were added to the ceils. As control, non
transduced celis were treated with the same doubling dilution of GCV. Ceils were
incubated for 6 days and viability was measured using the colorometric MTT assay.
Each condition was performed with 8 replicates and each experiment was repeated twice
and the data were presented as means of two experiments plus the standard deviation. A)
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Viability curves obtained with the mean of MRC-5 celis. B) Comparison of 1C50 at MOI
of 20 for both viruses.
B
3.3.4 Cytotoxic activity of AdTK-IRES-GFP and AdTK-cite-GK in Huvec celis
The non- cancerous human umbilical vein endotheliaÏ (Huvec) ceils were used
to test the cytotoxic activity of our viruses. The idea of choosing this ce!! une was related
to the recent publication that has shown that the co-expression of thymidine kinase and
guanylate kinase enhances vascular smooth muscle ce!! ki!ling and permits
administration of GCV in !ower doses as cornpared to the expression of thymidine
kinase alone (75). In this experiment, the ce!!s were transduced with MOI of 50.
Subsequently a set of binary dilutions of GCV starting from 20 jtg/ml to 0.04 jig/m!,
were added to the ce!!s. The resu!ts of cytotoxic activity of AdTK-IRES-GfP and AdTK
cite-GK viruses using different concentrations of GCV showed some better activity for
AdTK-IRES-GFP virus (Figure 20A). In comparison between the 1C50 for both viruses,
we have demonstrated that 1.6 fo!d lower GCV concentration is required for AdTK
IRE$-GFP to reach the 1C50 compared to AdTK-cite-GK (Figure 20B). The resuits ofthe
cytotoxic activity in Huvec ceil !ines confirmed the obtained resu!ts from three other cell
unes that the co-expression of GK gene with 1K does not improve the cytotoxic activity
ofTK gene.
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Figure 20: Comparison of the viability of the non-cancerous normal celis including
Huvec celis transduced with AdTK-IRES-GFP and AdTK-cite-GK viruses. Celis
were transduced with the respective AdVs at a MOI of 50. $ubsequently a set of binary
dilutions of GCV starting from 20 ig/ml to 0.04 jig/ml, were added to the ceils. As
control, non-transduced celis were treated with the same binary dilution of GCV. Ceils
were incubated for 6 days and viability was measured using the colorometric MIT assay.
Each condition was performed with $ replicates and each experiment was repeated twice
and the data were presented as means of two experiments plus the standard deviation. A)
AdTK-IRES-GFP Ad1X-Cfte-GK
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viability curves obtained with the mean of Huvec celis. B) comparison of 1C50 at MOI of
50 for both viruses.
3.4 Evaluation of the TK expression from AdTK-IRES-GFP and AdTK-cite-GK in
different celi unes
Ihe previous resuits of cytotoxic assay in different cancerous and non
cancerous ce!! unes demonstrated that the co- expression of GK gene with TK had no
improvement on cytotoxic activity of 1K to reduce the concentration of GCV. We can
hypothesize that this may be due to the lower 1K expression from AdTK-cite-GK virus
as compared to AdTK-IRES-GFP. In order to verify this point the expression of the 1K
was evaluated in MRC-5, U$7 and TOV2ÏG ceils (Figure 21). The resuits demonstrated
the same level of TK expression from both viruses in ail the ce!! unes. The leve! of 1K
expression was also eva!uated in Huvec ce!! une and showed the same level of TK
expression (resuits flot shown).
1 2 3 4 5 6 7 $ 9 KDa
+40
1: mock (non- infected MRC-5 celis)
2: MRC-5 ce!ls II Ad1K-IRES-GFP
3: MRC-5 ceils II AdIK-cite-GK
4: mock (non-infected U$7 ce!!s)
5: U$7 ce!ls II AdIK-IRES-GFP
6: U$7 ce!!s //AdIK-cite-GK
7 : mock (non- infected 10V-21G cel!s)
8 : 10V- 21G //AdTK-IRES-GFP
9: TOV-21G //AdIK-cite-GK
I!: infected with
Figure 21: Comparison of the TK expression from the AdTK-IRES-GFP and
AdTK-cite-GK viruses in MRC-5 (lanes 2 and 3), U87 (lanes 5 and 6) and TOV
21G celis (lane 8 and 9). The respective ce!!s were transduced with AdIK-IRES-GFP
and AdIK-cite-GK viruses at MOI of 50 for MRC-5 ce!!s and 20 for others. The
expression of 1K protein was eva!uated by western blot 4$h afier transduction.protein
samp!es were loaded at 2 tg of tota! protein on a 12% denaturing SDS-PAGE ge!.
Western b!ot analysis was performed by standard methods using a 1/1000 di!ution ofthe
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polyclonal rabbit anti-HSV-l TK antibody. A 1/2500 dilution ofthe HRP-coupled anti
rabbit serum were used as a second antibody.
3.5 Assessement of the enzymatic activity of GK from AdTK-cite-GK
It was shown in the previous resuits that the GK protein is expressed from
AdTK-cite-GK and 1K is expressed at equal levels from AdTK-IRES-GFP and AdIK
cite-GK viruses in 293 A ceils. We could speculate that while GK is expressed from
AdTK-cite-GK, it may flot be active. We thus tested its activity. The enzymatic activity
of GK was evaluated in two different ceil unes including 293A and HeLa ceils. Ihe
293A and HeLa ceils were transduced with AdTK-cite-GK and AdTK-IRES-GFP
vii-uses at MOI of 10 for 293A celis and MOI of 20 for HeLa ceils. This GK enzymatic
assay is based on the indirect measurement of both ADP and GDP formed ftom ATP and
GMP by coupling the above reaction to the pyruvate kinase and lactase dehydrogenase
reaction. The increasing transmittance at 340 nm associated with NADH oxidation was
measured by a spectrophotometer using a blue filter on each sample in the absence of
GMP every 20 seconds to evaluate the background rate and also in presence of GMP to
evaluate the total rate. Curies were obtained according to the %T340 versus lime (sec)
from the non-diluted 293A extracted samples (figure 22A), diluted 293A extracted
samples in a ratio of 1:3 (figure 223) and the non-diluted HeLa extracted samples
(figure 22C). The siope (AT/ AS) was calculated for each curie, which represent the
total rate in presence of GMP and the background rate in the absence of GMP. The level
of the total rate for AdIK-cite-GK in presence of GMP was the highest in all the
extracts. By looking at the figure 223 we deterniined that by diluting the 293A extracts
the ratio of the background rate was decreased. The GK activity was calculated
according to the difference between the total rate and the background rate and expressed
as A1340/min. The results of GK activity were calculated for the 293A and Hela ceils
transduced with AdTK-IRES-GfP and AdTK-cite-GK and summarized in Table II. The
resuits obtained from the non-diluted 293A extracts showed $.6X higher GK activity for
AdTK-Cite-GK compared to AdTK-IRES-GFP. In 1:3 diluted 293A we demonstrated
50X higher GK activity for AdIK-cite-GK as compared to the AdIK-IRES-GfP. Ihe
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huge difference in GK activity afier dilution is related to the decreasing amount of
background rate afier dilution. The resuits obtained from the non-diluted Hela extracts
showed 1 .7X higher GK activity for AdTK- cite-GK as cornpared to AdTK-IRESGFP.
The low difference in GK activity in HeLa cells is related to the high GK activity in
these cells in the absence of GK expressing AdTK-cite-GK virus.
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Figure 22: Evaluation of GK enzymatic activity. The 293A and HeLa celis were
transduced with AdTK-cite-GK and AdTK-IRES-GFP at MOI of 10 for 293A ceils and
MOI of 20 for Hela celis. The transduced 293A ceils were collected after 29 hours, but
for the Hela celis were coïÏected after 48 hours post infection. The activity was measured
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by reading the transmittance of each sample in the absence and presence of GMP every
20 seconds for a duration of 3 minutes at 340 nm. A) Curves obtained from the non
diluted 293A extracted samples. B) Curves obtained from the diluted 293A extracted
samples ai a ratio of 1:3. C) Curves obtained from the non- diluted Hela celis extract.
GK activity per min
TK-cite-GK TK-IRE$-GfP
non- diluted 293A extraction
transfected with: 6.9 0.8
1:3diluted293Aextraction 15 0.3
transfected with:
non-diluted HeLa cells 13.86 7.51
extraction transfected with:
Table II: Evaluation of the GK enzymatic activity. According to the figure 22 the
siope (ATlAS) was calculated for each curve. The estimated siope in the absence of GMP
is represented for the background rate and in presence of GMP is represented for the
total rate. The difference between the total rate and the background rate is represented by
the rate of guanylate kinase activity and expressed as AT340 per minute. Therefore the
guanylate kinase activity was calculated for the 293A and Hela ceils infected with
AdTK-IRES-GfP and AdTK-cite-GK and were compared.
3.6 Evaluation of the cytotoxic effect of increasing MOI of AdTK-IRES-GFP in
U$7 ceils as compared to the replicative AdTK-IRES-GFP virus
In order 10 achieve the clinical success, having a strong bystander activity is
critical. Here we tried to evaluate the potential benefit of constructing the replicative/
non-disseminative AdTK-IRES-GFP, by comparing the increasing MOI of non
replicating AdTK-IRES-GFP in U87 ceils. The goal of performing this assay was to
demonstrate whether the increasing MOI of the non-replicative AdTK-IRES-GFP and
consequently the increasing copy number of the virus in the celis would improve the
bystander effect. U87 celis were transduced with AdTK-IRES-GFP at the MOIs of 20,
50, 100 and 200. The bystander activity vas assessed by mixing the transduced and non-
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transduced celis at different ratios in presence of GCV. The bystander effect of the
AdTK-IRE$-GFP at different MOIs showed no significant difference (Figure 23A). The
percentage ofthe transduced celis required to reach the 50% ce!! death was evaluated for
ail the four conditions (Figure 233). The T-test was performed on the resuits ofIC50 of
the transduced ceils at four different MOI and did not show any statistical difference.
The resuits of western blot analysis showed that there is a correlation between the
increasing in the MOI of AdTK-IRES-GFP and the increasing level of 1K expression
(resuits not shown).
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Figure 23: Comparison of bystander activity between increasing MOI of AdTK
IRES-GFP in U87 celis. U87 Ceils were transduced with AdTK-IRES-GFP at the MOIs
of 20, 50, 100, and 200. The transfected ceils were mixed with the non- transfected ceils
24h post- infection at different ratios as following: 50%, 33%, 20%, 11%, 6%, 3%,
1.5%, 0.8%, 0.4%, 0.2%. Then GCV were added at the concentration of 2 jtg/ml. GCV
were flot added to the controls using the exact ratio of transduced celis. Celis were
incubated for 6 days and celi viability were measured using a colorimetric MTT assay.
Each condition was performed with $ replicates and each experiment was performed two
times and the data were presented as means of two experiments plus the standard
deviation. A) Curves obtained with the mean of U87 celis. B) Evaluation of the 1C50 of
transduced celis.
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In the other experiment we tried to confirm more directly the resuits from the
previous experiment, the replication of the AdTK-IRES-GFP was generated by co
infection of the non-replicative AdTK-IRES-GFP with the replicative Ad(PS+)CU
IRES-GfP-EIA. U$7 celis were transduced with AdTK-IRES-GfP at MOI of 20 and in
the other scenario were co-infected with Ad(PS+)CU-IRES-E1A at MOI of 20. The
bystander activity of both viruses was evaluated by mixing the transduced and non
transduced celis at different ratios in the presence of GCV. The bystander effect with or
without replication showed no difference (Figure 24A). The T-test was performed on the
1C50 at the desired MOI and showed no statistical difference (figure 24B). These resuits
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confirmed that amplifying the copy number of the AUTK-IRES-GfP via AdV replication
had no significant improving effect on the anti-tumor activity in a bystander assay.
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Figure 24: Comparison of bystander activity of AdTK-IRES-GFP with or without
replication. U87 Celis were transduced with AdTK-IRES-GFP at MOI of 20 and in the
other scenario were co- transduced with AdTK-IRES-GFP and Ad(PS+) CU-IRES-E1A
at MOI of 20. The transduced ceils were mixed with the non- transfected ceils 24h post
infection at different ratios as following: 50%, 33%, 20%, 11%, 6%, 3%, 1.5%, 0.8%,
0.4%, 0.2%. Then GCV were added at the concentration of 2 ig/ml. GCV were not
added to the controls using the exact ratio oftransduced celis. Ceils were incubated for 6
days and ceil proliferation were measured using a colorimetric MTT assay. Each
condition was performed with 8 replicates and each experiment was performed two
times and the data were presented as means of two experiments plus the standard
deviation. A) Curves obtained with the mean of U$7 cells. B) Evaluation of the 1C50 of
transduced celis.
3.7 The effect of GCV on viral replication
It has been shown that the administration of GCV diminish the anti-tumor
efficacy of the replication-competent HSV-TK expressing vectors in a peritoneal
carcinomatosis mode! (82). In order to test the effect of GCV on vira! growth, the 293A
cells were transduced with the AdTK-IRES-GFP at MOI of 10. GCV was added at
concentrations of 2 ig/m! and 10 tg/ml. We then compared the obtained viral progeny
in presence or absence of GCV (figure 25). Adding GCV at the concentration of 2 ig/ml
resulted in a decrease in viral titer by about 30-fold as compared to the control. Using a
higher concentration of 0CV of about 10 1g/m! resu!ted in lower viral titer of about 60
fold compared to the control. Therefore the resuits showed that the increasing
concentration of the 0CV has a negative effect on viral replication. This can be
explained by the fact that GCV acts as a virostatic agent and aborts viral multiplication.
Most likely the decrease in virus progeny is due to decrease in virus rather than the
decreased ce!! viability because the cytopathic effect of the cells starts after 3 days and
by that time the production of viral progeny is completed.
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Figure 25: Evaluation of the effect of GCV on the replication of AdTK-IRES-GFP
in 293A celis. 293A celis were transduced with the AdTK-IRES-GfP at MOI of 10.
GCV was added at a concentration of 2 jig/ml and 10 jig/mJ 3 hours post infection.
Titration was performed for the celis treated with GCV and compared with the
transduced celis in the absence of GCV as a control to determine the effect of the GCV
on viral replication.
1K-IRES- 1K-IRES- TK-IRES
GFP, -GCV GFP, «3CV GFP, +GCV
(2Jg/mL) (10 pg/mL)
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3.8 Construction and characterization of the replicative AdVs expressing CR5GFP
cassette from a region between RITR and E4
Although replication of AdV was flot beneficial to suicide gene therapy with
HSV-tk, resuits generated in our laboratory have shown that it is very beneficial with the
CU (CD::UPRT) suicide gene (Bourbeau in preparation). In order to have a replicative
AdV, the E 1 region of the AdV should be conserved and the transgene should be
inserted in the region other than El. Several attempts were performed in our laboratoiy
in order to generate the replicative recombinant viruses. This part of the study was done
in parallel to the previous study, which was related to the construction of the non
replicative recombinant AdVs expressing the desired suicide genes and the assessment
of their cytotoxic activity. In this study we tried to find the best position and
configuration to insert the transgene between the E4 region and RITR in order to allow
us in future to insert our suicide genes out of the E 1 region. We hypothesized that the
replicative adenoviruses that produce higher level of suicide gene expression within
cancerous celis could lead to more effective cytotoxic activity with lower concentrations
ofthe prodrug.
The production of the replicative recombinant adenoviruses was a two step
process. First step was the construction of the transfer vector and the second step was the
construction of the recombinant virus via positive selection method. In order to construct
the transfer vector, GFP under the control of CR5 (cumate inducible promoter) was
inserted in a region between the RTTR and the first openen reading frame (orfi) of E4
region in pAdE4ext and/ or between the RTTR and orf6 of E4 in pAdE4-orf6+ transfer
vector and as well the P5 was inserted in the PacI site of the respective transfer vectors.
In the CR5 (Cumate inducible promoter) the cumate operator (CuO) is located upstream
of the minimal CMV5 promoter (TATA box). cTA is a chimeric transactivator and is
formed via a fusion between the carboxylic end of CymR and the activation domain of
mammalian transactivator VP16. Since the DNA binding ability of CymR is regulated by
Cumate binding, it is possible to regulate its binding to DNA and hence the
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transactivation of the transgene by the transactivator could be controled (see Figure 4).
At the next step the recombinant AdVs were selected by positive selection method as
described in matherial and methods (see 2.5.2). In this method the recombination was
accomplished between the linear transfer vectors and the Ad5AP$ as a backbone in
293A ceils.
3.8.1 Possible recombinations bebveen the tranfer vectors expressing CR5GFP
cassette from a region between RITR and E4 and the Ad5APS virus in 293A celis
In our platform because ofthe presence ofthe PS gene away from the transgene,
there were two homology regions upstream and downstream of the PacI site of the
linearized transfer vectors with Ad/APS backbone virus. The pAdE4ext transfer vector
has a 1.7 Kb homoÏogy region upstream and 5 Kb homology region downstream of the
PacI site with Ad/APS backbone virus. On the other hand, the pAdE4orf6ext transfer
vector has a 1.7 Kb homology region upstream and a 2 Kb recombination region
downstream of the PacI site. In theory the recombination between the homology region
upstream of the ectopic P$ in PacI site with the Ad/APS backbone would generate a
recombinant AdV carrying the ectopic PS gene including the CR5GFP expression
cassette. This recombinant virus can be selected by positive selection over the Ad/APS
backbone on 293A ce!! unes (Figures 26 and 27).
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Figure 27: Schema of the expected recombination in 293A ceils. Recombination
between the pAdCR5GFP-L/E4orf6t’PS+ (CR5GfP toward lefi ITR) and/ or pAd
pAdCR5GFP-RJE4orf6JPS+ (CR5 GFP toward right ITR) transfer vector with the
z
AdCR5GFP-R/PS+
PS CR5GFP
N
Ps
E1+,E3-, E4+
AdCR5G FP-L/PS+
CR5GFP
Figure 26: Schema of the expected recombination in 293A celis. Recombination
between the pAdCR5GFP-L/PS (CR5GFP toward lefi ITR) and/ or pAdCR5GfP-R!P$
(CR5GfP toward right ITR) transfer vector with the AdAPS viral backbone and the
expected resulting viruses.
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PS CR5GFP PS
____________________________
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AE4orf6+ AE4orf6+
E1+,E3-, E4-, Orf6+
AdAPS viral backbone and the expected resulting viruses.
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furthermore, the recombination between the hornology region downstream of
the ectopic PS in PacI site with Ad/APS backbone virus would give an AdV lacking the
ectopic PS gene but carrying the transgene cassette (recombination 1 in Figures 2$ and
29). This recombinant virus is dependent on the PS positive virus or the P$ expressing
celi une (293-PS) for its growth. However the double recombination between both sides
of the ectopic PS in PacI site of the transfer vector with Ad/APS backbone virus would
resuit in having an Ad/PS+ virus lacking the transgene (recombination 1 and 2 in Figures
28 and 29).
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Figure 22: Schema of the possible double recombinations (1 and 2) and single
recombination (1) in 293A ceils. Double recombinations (1 and 2) and single
recombination (1) between the pAdCR5GFP-L/PS+ and/ or pAdCR5GFP-R]PS+
transfer vector with AdAPS viral backbone and the possible resulted viruses.
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Figure 29: Schema of the possible double recombinations (1 and 2) and single
recombination (1) in 293A ceils. Double recombinations (1 and 2) and single
recombination (1) between the pAdCR5GFP-L/E4orf6/PS and/ or pAdCR5GFP-R/E4
orf6/PS transfer vector with AdAPS viral backbone and the possible resuÏted viruses.
Afier the production of the recombinant viruses via positive selection, plaque
purification assay was performed to isolate the plaques. Afler 10- 12 days the
recombinant viruses expressing CR5 GfP cassette were easily identified by fluorescent
microscopy as green plaques on the monolayer culture (see 2.5.2). Ail the individual
plaques were analyzed by PCR for the extracted viral genome for the presence of
CR5 GFP cassette (results flot shown). Among the viruses only the population of
AdCR5GFP-R/PS was mixed with the Ad5PS(E3-TK) virus and the purification ofthe
AdCR5GFP-RJP$ was performed in 293-PS cell une. In our attempt to constmct the
AdCR5GFP-L/E4orf6 7PS(E3 -1K) and AdCR5 GFP-R!E4orf6 /PS(E3 -1K)
recombinant viruses, the plaques were perfectly isolated but we did not succeed to purify
away the pAdCR5GFP-L/E4orf67PS virus in the mixture from the other unwanted
recombinant viruses.
The characterisation of the recombinant replicative as well as the control
viruses used in this study are described below.
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AdCR5GFP-RIPS
AdCR5GFP-R/PS express CR5GfP cassette ftom a region between RITR and
orfi region of f4 and the orientation of the cassette is toward the right IIR. This virus is
a replicative virus in the PS compiementing ce!! unes including 293-PS and it performs a
single round of replication in other non-complementary ccli !ines. This virus was
constructed via recombination between the !inear pAdCR5GfP-R/PS transfer vector
and Ad5APS as demonstrated in figure 28. AdCR5GFP-R/PS virus was first selected as
a green plaque on 293A celis and the resuits of PCR for the presence of the CR5GfP
cassette on the extracted vira! genome showed that it was mixed with the white AdPS
virus. Severa! plaque purifications on PS complementing ceils (293-PS) were performed
to purify the AdCR5GFP-R/PS virus. The schema of the AUCR5GfP-R’PS is shown in
figure 30.
CR(3F P
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Figure 30: Schema of the AdCR5GFP-RJPS recombinant adenovirus
AdCR5GFP-RJPS
AdCR5GfP-R’PS is a rep!icative AdV expressing CR5GfP cassette from a
region between right ITR and orfi region of E4 and the orientation of the cassette is
toward the RITR. This virus was constructed from the AdCR5GFP-RIPS virus as a
backbone by re-inserting the PS fragment into its original site as previously explained in
the material and methods (sec 2.5.3). The schema of the AdCR5GfP-RIPS is shown in
figure 31.
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Figure 31: Schema of the AdCR5GFP-RJPS recombinant adenovirus
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AdCR5GfP-L/PS(E3-TK)
AdCR5GfP/PS(E3-tk) is a replicative AdV expressing CR5GFP cassette from
a region between RTTR and orfi region of E4 and the orientation of the cassette is
toward the lefi TIR. In this virus the E3 region is deleted and replaced by the PS gene
under the control ofTK promoter. Ihis virus was constructed via recombination between
the linear pAdCR5GFP-L/PS transfer vector and Ad5APS as shown in Figure 26. The
schema ofthe AdCR5GfP-L/PS(E3-TK) is shown in Figure 32.
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Figure 32: Schema of the AdCR5GFP-L/PS(E3-TK) recombinant adenovirus
AdCR5GFP-RIE4orf6JPS(E3-TK)
AdCR5GfP-E4orf6!PS(E3-IK) is a replicative AdV expressing CR5GFP
cassette from a region between RITR and orf6 region of E4 and the orientation of the
cassette is toward the right TIR. The PS gene is deleted at the original place but the PS
gene under the control of 1K promoter is placed in the F3 deleted region. Ihe
construction of this virus was perforrned via recombination between the linear
pAdCR5GFP-L/E4orf6t’PS+ transfer vector and Ad5APS as shown in Figure 27. Ihe
scherna ofthe AdCR5GFP-RJE4orf6t’PS(E3-IK) is shown in Figure 33.
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Figure 33: Schema of the AdCR5GFP-WE4orf6tPS(E3-TK) recombïnant
adenovirus
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AdCR5GFP-L/Ei
AdCR5GFP/EF is a non-replicative AdV expressing CR5GFP from the El
region and the orientation of the cassette is toward the lefi ITR. The construction of this
virus was described before in material and methods (see 2.5). The schema of the
AdCR5GFP-L is shown in Figure 34.
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Figure 34: Schema of the AdCR5GFP-L/E1 recombinant adenovïrus
AdCMV5GFP-LIEf
AdCMV5GFP/E1 - is a non-replicative AdV expressing CMV5GfP from the El
region and the orientation of the cassette is toward the left ITR. The construction of this
virus is described before in material and methods (see 2.5). The schema of the
AdCMV5GFP-L/ Efis shown in figure 35.
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Figure 35: Schema of the AdCMV5GFP-LIEF recombinant adenovirus
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AdE37E4orf&
AdE37E4orf6 is a non-replicative AdV that does flot express any transgene.
The construction of this virus is described before in material and methods (see 2.5). The
schema ofthe AdE37E4orf6 is shown in Figure 36.
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Figure 36: Schema of the AdE37E4orf6 empty vector
AdPTG36O2
The AdPTG36O2 is a wild type virus in which ail the regions (E!, E3, E4 and
PS) are intact (8). The shema ofthe AdPTG36O2 is shown in Figure 37.
P5 E3 E4 RITR
Figure 37: Shema of the AdPTG36O2 wild type virus
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Ihe summary of the status of different deletions in different regions of viral
genome is classified in table III.
virus El PS E3 E4 Expression cassette-orientation
t\dCR5GFPR/PS + - ± + DR5GfP-RJTR
tSdCR5GFPRJPS + + (on) ± + CR5GFP-RITR
dCR5GfP-L/PS(E3-tk) + + (E3-tk) - + 2R5GFP-RITL
dCR5GFP-RIE4orf6/PS(E3-tk) + + (E3-tk) - - (orf6+)CR5GFP-LITL
dCR5GfP-L/EF
- + (on) - + 2R5-GfP-LITR tEl)
dCMV5GFP-L/EF
- + (on) - + CMV5-GFP-LITR (El)
dE3-/E4orf6 + + (on) - - (orf 6+) Jone
dPTG36O2 + + (on) ± + one
Table III: Nomenclature of the AdVs. Ihe AdVs were named on the basis of their
transgene and their promoter and other deletions in AdV regions. The abbreviation for
the transgene is GfP for Green Fluorecent Protein. Ihe promoters for transgene
expression are CMV5-300, a modified Cytomegalovirus immediate-early promoter or
CR5, a Cumate inducible promoter. The orientation of the inserted transgenes is shown
as R (toward the right TIR) or L (toward the lefi ITR). The viruses that are P$ deleted
are shown as P$- and the PS+ viruses are represented for PS in the original position;
AdPS+(E1-mlp), PS is in El region under the control ofmlppromoter or AdPS+(E3-tk),
PS is in E3 region under the control of HSK-TK minimal promoter. AdVs with E3
deleted were shown as E3- and those with E4 deletion except for Orf6 are shown as E4-
orf6+.
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3.9 Analysis of GFP expression from recombinant AdVs in both OFF and ON
conditions in the presence or absence of AdcTA in 293Acells
In this experiment in order to have an OFF condition, the 293A ceils were
infected at MOI of 50 with our recombinant viruses expressing GFP under the control of
CR5 promoter, a cumate inducibie promoter, and the non-replicative virus expressing
GFP under the control of CMV5 promoter, a constitutive promoter. For ON condition ail
the viruses were co-infected with the AdcTA at MOI of 10 for the transactivator virus
and MOI of 50 for the recombinant viruses (Figure 38).
Among ail the viruses AdCR5GFP-L/PS+(E3-tk) showed the best induction
factor. The mean of GFP expression in ON conditionlOFF condition at 24 and 4$ hr post
infection demonstrated the induction factor of 36 and 44 respectiveiy. The best induction
factor is related to the lowest background in off condition as compared to the
AdCR5GfP-RIPS+. In ail the E3+ AdVs including AdCR5GFP-RJPS and AdCR5GFP-
R’P$+, the deletion of PS gene in non-compÏementary ccii une (293A) has no significant
impact on the ievei of GFP expression under the ON or OFF conditions. In AdCR5GFP-
E4orf6/P$(E3-tk), which is the only virus with E4 deietion and with the direction of
the transgene toward right ITR, the ievei of background (mean of GFP expression in
OFF condition) was increased about 3 times. It seems in this virus with the deletion of
E3 and F4 regions, the MLP promoter is situated doser to the transgene and exerts a
higher influence on the expression of GFP. By comparing ail the recombinant AdVs
expressing the CR5 GFP from the E4 region with the one expressing the same expression
cassette from Fi region, we conciuded that ail the AdVs with CR5 promoter expressed
the GFP in ON condition (presence of AdcTA) better or equivaient to the AdCR5-GFP-
L/EF that has the same expression cassette in El region after 48h. On the other hand the
resuits of comparing the recombinant AdVs expressing the CR5GFP from the E4 region
with the one expressing GFP under the control of CMV5 constitutive promoter showed
that ail the AdVs with the CR5 promoter expressed the GFP at 48hr under ON condition
(presence ofAdcTA) at the same level or better than the AdCMV5GFP-L/EF.
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The level of mean GFP expression after 48h post infection with AdcTA is
remarkably increased in comparison to its expression level afier 24h and it could be
related to the augmentation in the level of the transactivator by that time. Our resuits
suggest that the insertion of the expression cassettes near the right IIR resuïted in
transgene expression better than in the El region after 4$h. Our data showed that in
order to generate the replicative recombinant viruses expressing potentially toxic
proteins, the pAdE4t’PS(E3-tk) backbone or pAdE4orf61JPS(E3-tk) in order to
increase the transgene capacity with the direction of the transgene toward the lefi ITR, is
the best configuration to have the lowest basal gene expression in OFF condition.
Figure 38: Analysis of GFP expression of the replicative AdVs with CR5 promoter,
a cumate inducible promoter, in the presence or absence of AdcTA (an AdV that
express cTA protein as a transactivator). 293A ceils were transduced with each adV at
MOI of 50 (Off condition) or co-infected with AdcTA at a MOI of 10 (On condition). At
24h and 48h post infection, the expression of GFP was measured by flow cytometer.
Each experiment was repeated twice and mean of GFP expression were presented as
means oftwo experiment plus the standard deviation).
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3.10 Analysis of GFP expression of the recombinant AdVs expressing GFP with
CR5 promoter, a cumate inducible promoter, in presence or absence of cumate in
HeIa-cTA ceils
In this experiment HeLa-cTA ceils were infected with each of the recombinant
replicative AdVs including AdCR5GfP-RIPS, AdCR5GfP-R!PS, AdCR5GfP-
L/PS(E3-tk), AdCR5GfP-R/E4orf67PS(E3-tk) in presence (Off condition) or
absence (ON condition) of cumate. The concentration of the cumate was 200 jig/ml.
Then the expression of GFP was measured 24h and 48 h post infection by flow
cytometry (figure 39).
The resuits have demonstrated that deletion of the PS gene in non
complementary ce!! une (HeLa-cTA) has no significant impact on induction factor
(mean of GfP expression in ON condition! Off condition). This resu!t, mainly obtained
by comparing the AdCR5GfP-R/PS and AdCR5GfP-R/PS+ viruses, revealed that their
on!y difference is related to the presence or absence ofthe P$ gene from the original site.
By looking at the resu!ts of the AdCR5GFP-R’PS+ and AdCR5GfP-L/PS+(E3-tk)
viruses we conc!uded that the orientation of the transgene in E4+/E3+ backbone at 4$h
post infection did flot influence the induction factor. The comparison between the E4+
viruses and E4orf6 virus showed that the leve! of background (mean of GfP expression
in OFF condition) increased about 2 times in AdE4orf6 afier 4$h. This part of the
results confirmed the conclusion that was obtained from the previous resu!ts that the
deletion of E3 and E4 regions resu!ts in a higher influence of the MLP promoter on the
expression of transgene in a configuration toward RITR. Fina!!y the results demonstrated
the overa!! high level of backgroud (mean of GFP expression in OFF condition) for a!!
the viruses as compared to the previous resu!ts. We assumed that the problem is re!ated
to the leakiness of the CR5/cTA system in this current configuration.
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Figure 39: Analysis of GFP expression of AdVs with CR5, a cumate inducible
promoter, in presence or absence of cumate from the cTA expressing celi unes
(HeLa-cTA). Celis were transduced with each AdV at MOI of 50 in presence (Off
condition) or absence (On condition) of cumate. 24h and 48h post-infection, the
expression of GfP was measured by flow cytometer. for statistical analysis each
experiment was repeated twice and mean of GfP expression were presented as means of
two experiments plus the standard deviation.
3.11 Evaluation of PS+ viral progenies expressing GFP under the control of CR5
promoter, a cumate inducible promoter in 293A ceils
In this experiment in order to compare the titer (viral progenies) of replicative
and non-replicative viruses, 293A cells were transduced with each AdVs
D OFF-24h DON-24h
OOFF-48h •ON-48h
were measured with a TCID50 assay on 293A celis and in 96 wells. In order to have a
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reliable resuit for comparing viral titres, the titer was calculated as a total viral progeny
produced by each celi before harvesting the virus (Figure 40).
The resuits showed that the highest titre is obtained by the wild type adenovirus
that has no deletion in viral regions. The titre of the empty vector with the deletions in
E3 and E4 regions but orf6 showed reduction in viral progeny by 3-fold. The reduction
of viral progeny could be due to the deletions in E3 and or E4 regions. It has become
apparent that each E4 protein independently augments viral DNA replication and late
protein synthesis and the production of progeny virions(13). It has been shown that the
E3 products are not essential for viral replication in vitro. However, in some
applications, it might be desirable to retain or even increase the expression of some £3
such as adenovirus death protein (E3-l 1.6K), which facilitates the release of viral
particles from the infected cells(7).
The titer of the replicative AdCR5GfP-R!PS+ showed the reduction of about 4-
fold compared to the wild type AdPTG36O2. The difference between the titer of two
viruses could be related to the insertion of the CR5 GFP cassette in the region between
the E4 and RITR region. It seems that the insertion of the transgene has oversized the
packaging capacity and affected the production of viral progeny. It has been shown that
Ad can package up to 2 Kb above its size (38Kb) but this can reduce viral growth (83).
The comparison between AdCR5GFP-E4orf6/PS(E3-tk) and Ad/E3E4orf6empty
vector showed a reduction of 2.4 fold in viral progeny. It seems that the deletion in E4
region provided enough space for transgene insertion but the difference in the titer could
be related to the suboptimal expression of PS gene under the control of tk promoter in
- ± + - . ..AdCR5GFP-R!E4 orf6 /PS (Ei-tk) virus. In addition, the comparison between the
AdCR5GFP-L/PS(E3-tk) and AdCR5GFP-RJPS showed the reduction of $ fold in
viral titer. The difference in the titer could be related to the deletion in E3 region and
suboptimal expression of PS under the control of TK prornoter. Results generated in our
laboratory have shown that the suboptimal expression of P$ from the 1K promoter could
affect the viral progeny by 5 fold (Gagnon et aï, in preparation).
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The comparison between the viruses expressing GFP from El region and or
from a region between the E4 and RJTR under the control of the cumate inducible
promoter (CR5) or the constitutive promoter (CMV5) demonstrated that the growth of
AdVs was flot significantïy affected by the insertion of a cassette in the region between
E4 and right ITR region.
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Figure 40: Comparison of PS+ viral progenies of the recombinant replicative
adenoviruses expressing GFP under the control of CR5 promoter, a cumate
inducible promoter, with the controt viruses in 293A ceils. Cells were transduced
with each AdV at MOT of 50 in triplicate. At 48h post infection the transduced celis were
harvested and virus progeny were measured with a TCID50 assay on 293A celis in 96
wells plate. The viral titer were presented as TCID50 / celi. For statistical analysis each
experiment was repeated in triplicate and the data were presented as means of three
experiments plus standard deviation.
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3.12 Effect of the gene expression on virus progeny
In order to evaluate the effect of the induction of the transgene on the viral
progeny the HeLa-cTA cells were transduced with AdCR5GfP-R’E4orf6+/P$+(E3-tk)
and AdCR5GFP-R!PS+ viruses at MOI of 50 in the presence (OFF condition) and
absence (ON condition) of cumate (as explained in Figure 40). At 4$h post infection,
virus progeny was rneasured with a TCID50 assay on 293A ceils (Figure 41).
The resuits showed that although the expression of GFP was 1.5 to 3.6 times
higher under the induction condition in HeLa-cTA cells (figure 30) for the AdCR5GFP-
R’ E4orf6+/PS+(E3-tk) viruses and AdCR5GfP-RIPS+, the viral progeny was flot
reduced. Therefore, we could conclude that the transgene expression did flot affect the
viral progeny.
DOFF (cumate+) ØON (cumate-)
Figure 41: Evaluation of the gene expression in virus progeny. HeLa-cIA celis were
transduced in duplicate with AdCR5GFP-R/PSand AdCR5GFP-R’E4orf67PS(E3-tk)
at MOI of 50 in the presence and absence (On condition) of cumate. At 4$ h post
infection, virus progeny was measured with a TCID50 assay on 293A cells in 96 wells
plate. Each experiment was repeated twice and the titer/cell was presented as means of
two experiments plus the standard deviation.
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Chapter 4:
Discussion
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4.1 Combined suicide gene therapy- with TK and GK
The fundamental goal of this Masters project was based on optimization of the
adenovirus vectors in order to have an efficient vector with a strong expression of
suicide genes and to to reduce the level of prodrug. One part of the project was to
evaluate the activity of combined suicide gene therapy in cancer celis. It has been shown
in several publications that using two suicide genes was more beneficial as compared to
single suicide gene for cancer therapy. In our laboratory, a study has confirmed the
superiority of the combined CD::UPRT (cytosine deaminase:: uracil phosphorybosyl
transferase) over CD alone in several tumor cells both in monolayer and spheroid model
($4).
In this study we evaluated the cytotoxic activity of AdTK-cite-GK,
coexpressing two suicide genes thymidine kinase (TK) from herpes simplex virus 1 and
human guanylate kinase (GK) in a dicistronic cassette as compared to AdTK-IRES-GFP,
expressing one suicide gene (TK) in a dicistronic cassette with GFP. HSV-TK converts
the nucleotide analogs including GCV, into its monophosphate stage via
phosphorylation. Once phosphorylated, GCV-P requires further phosphorylation by
cellular enzymes to produce its toxic form, which terminats DNA synthesis. GK can
carry out both subsequent phosphorylation steps and has been reported to be present in
many tissue extracts. It has been demonstrated in a recent publication that co-expression
of GK with TK in noncancerous ceils enhances prodrug celi killing in vitro and
suppresses vascular smooth muscle ceil proliferation in vivo leading to administration of
GCV at lower doses (75). It has been shown that the high doses of GCV are associated
with side effect such as nephrotoxicity and bone marrow supression (75).
In our study we evaluated the coexpression of GK with TK to test whether the
coexpression of GK with 1K might enhance phosphorylation of GCV in cancer cells. In
order to accomplish this objective, the cytotoxic activity of AdTK-IRES-GFP and
AdTK-cite-GK viruses were characterised in two cancerous celi unes: U87 and TOV
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21G. The concentration of GCV was measured at IC50 in order to compare the cytotoxic
activity of both viruses (figures 17 and 18). Ihe resuits demonstrated that the
coexpression of GK with TK did flot improve the cytotoxic effect of 1K in cancer celis.
In order to confirm the resuits obtained in cancer ceils, we evaluated the cytotoxic
activity of our viruses in normal celis. We used the Huvec celis, which are very similar
to the celis that were used in the previously publication (75) in order to see whether we
could get the same results as them (Figure 20). MRC-5 celis were used as another
normal celi une (Figure 19). Ihe results of the cytotoxic activity of our viruses in normal
celis confirmed the resuits of the cancerous celis that the GK gene has no superior effect
on cytotoxic effect of 1K. The expression of 1K and GK and the enzymatic activity of
GK were evaluated in order to support our conclusion. The expression of the 1K gene
from AdIK-IRE$-GFP and Ad1K-cite-GK in four different ceil unes were evaluated
and showed the same level of expression from each cell une (Figure 21). The expression
of GK gene and also the enzymatic activity of GK were characterised and showed that
the GK gene is perfectly expressed and is enzymatically active (Figures 16 and 22).
At the end we compared our results with the data shown in abovementioned
publication that demonstrated the improvement in cytotoxic activity with coexpression
of 1K and GK in vascular smooth muscle ceils (75). In this publication the coexpression
of GK with 1K in comparison to the TK alone was shown as a result of a transfection
experiment. Ihey have shown that the transfection of vascular cells with TK-cite-GK
(pAdEF 1 aTK-cite-GK) could increase cell killing by 2-fold as compared to 1K alone
(pAdEF1Œ-IK) at a dose of 0.5 tM GCV. lhey then compared the cell viability of the
infected vascular cells with three different TK-cite-GK expressing viruses under the
control of three different promoters. They evaluated the effect of the coexpression of GK
with TK via different promoters on reducing the level of the prodrugs ganciclovir (GCV)
and acyclovir (ACV). lhey neyer confirmed the resuits of transfection with their
constructed viruses to test whether the same difference in celÏ killing was obtained via
coexpression of TK and GK compared to TK alone was reproducible. Since the results
of transfection could vary from one transfection to another due to the quantity of DNA,
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the resuits of transfection need to be confirmed via transduction, we can raise doubt
about the validity oftheir resuits.
4.2 Correlation between the increasing of TK and the bystander effect in U87 celis
Until very recently gene therapy either developed AdVs expressing suicide genes
or oncolytic AdVs. Because of their efficacies, new AdVs are now combining oncolysis
and suicide gene therapy ($5;$6). Since the coexpression oftwo suicide genes including
1K and GK did flot show a significant improvement in cytotoxic activity as compared to
1K alone in several cancerous and noncancerous celis, in this part of study we evaluated
the relation between the increasing amount of suicide gene (1K) and the cytotoxic
activity in cancer ceils. The objective was to increase the viral genome carrying the
suicide gene either through the increase of MOI or through the replication and to test the
consequences on cytotoxic activity and bystander effect.
Our data have shown that increasing copy numbers of the suicide gene (TK) via
increasing the MOT of AdTK-IRES-GfP virus from 20 to 200 in U$7 ceils has no
improved on the bystander effect in presence of GCV (figure 23). It has been shown in a
publication that there is a proportional increase in transgene expression and the MOI (up
to MOI of 1000) in permissive and non-permissive celis infected with AdCMV5-GfPq
virus (7$). Ihe resuits of the western blot demonstrated that there is a correlation
between the increase in MOI of AdTK-IRES-GfP and the 1K expression (resuits flot
shown). We showed that there is about 10- fold difference for 1K expression between
the MOI of 20 and 200, which confirmed the resuits of abovementioned article. On the
other hand we tried to amplify the AdTK-TRES-GfP genome through replication by co
infecting it with an E1A+ virus at MOI of 20. The resuits shown in figure 24 revealed
that amplifying the AdTK-IRES-GFP did not improve the bystander effect as compared
to the nonreplicative AdTK-IRES-GfP virus. It seems that the correlation between the
high level of TK expression and the bystander assay in cancer celis is affected by
different factors. As already discussed in the introduction section a primary major
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limitation of the bystander effect in HSV-TKJGCV system has been attributed to gap
junction dependence, involving the passage of cytotoxic phosphoiylated GCV
derivatives between the cells.
On the other hand we evaluated the effect of the GCV on the replication of
AdTK-IRES-GfP in 293A cells. Our data showed the decrease in viral progeny by
increasing the concentration of GCV. Our resuits confirmed the virostatic effect of GCV
as shown by another group ($2). This leads us to believe that the combination of HSV
1K suicide gene and oncolysis may not result in much improvement and is may provide
as another limitation for bystander effect in replicative/dissiminative platform.
4.3 Introducing an effective configuration for cloning between E4 and RITR region
Although repiication of AdV demonstrated no benefit to suicide gene therapy
with HSV-tk in our platform, results generated in our laboratory have shown that it is
favorable with CU suicide gene (Bourbeau et al., in preparation). In an attempt to
develop a replicative adenovirus expressing CD::UPRT suicide gene the EÏA gene of
adenovirus was introduced downstream of the transgene, following an internai ribosomal
entry site (IRES) and this expression cassette replaced the El region of adenovirus
(Bourbeau et al., in preparation). The presence of E1A allowed the replication of the
viral genome and the expression of viral proteins. But this E 1 A+ virus showed difficulty
for viral growth and production of viral progeny compared to the wild type virus. Based
on the other publications this alteration in viral growth is related to the absence of E1B
55KDa gene. It has been shown that E1B55KDa- deleted mutants replicate significantly
less well than Ad5WT ($7). Responsible for this phenotype is most likely the iacking
ability of the E1B 55KDa gene product to relieve the restrictions on adenoviral
replication established by the ce!! cycle ($8) and to facilitate the transportation of viral
mRNA during the Ïate stage of a lytic adenoviral infection (89).
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In another part of our study, we have explored another approach to introduce a
more efficient replicative AdV in order to overcome the limitations of the current
replicative AdVs. We tried to introduce the transgene in a region other than El, which
was between the E4 region and the RJTR. It has been shown by other groups that in
order to develop a tissue specific transgene expression, placing the promoter in close
proximity to the E1A enhancer resuits in several fold increase in transgene expression in
undesired tissues as compared to the cloning site near the right IIR (90). In this study we
determined the best strategy for cloning the transgene (GFP) under the control of cumate
regulatory promoter (CR5) in a region between E4 and RITR. We tried to find a
configuration with the highest transactivation in presence of the transactivator and the
lowest background in the absence of the transactivator. We used two different adenoviral
vectors, one E4 completed and the other F4 deleted and orf6 added in order to have
about 2.5Kb extra space for the transgene insertion. In this study we analysed the GfP
expression of the replicative viruses in 293A ceils co-transfected with AdcIA as well as
in Hela-cTA ceils that stab!y expresses cTA protein (Figures 38 and 39). Our data have
shown that the the cloning of the CR5 GFP transgene in a region between E4 and RITR
with the orientation toward the left TIR gives the best induction factor with the minimal
backgroung (off condition). We demonstrated that the cloning of the CR5GFP toward
the right ITR in an E3 and F4 deleted backbone had the highest GFP expression as a
background (off condition). It seerns that in the F3 and F4 deleted platform MLP
promoter, which is situated doser to the transgene could strongly enhance the GFP
expression. We observed that in 293 A ceils the level of GFP background in the absence
of cIA protein (in the absence of cotransfection by cIA virus) is increased afier 48h post
infection. Ihe same resuits were obtained from Hela-cTA ceits in presence of cumate
(OFF condition) and these resuits are related to the leaky expression of the transgene
from CR5 regulatory promoter in the current platform.
In order to determine whether the transgene expression has any effect on viral
progeny, we tested the effect of induction of the transgene expression on two different
replicative viral progeny in Hela-cIA ceils in the off and on conditions. The resuits
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showed that the overexpression of the transgene has no disadvantageous effect on viral
growth (figure 41). In addition, we evaluated the titre of our replicative viral progenies
and the first generation AdVs and the wild type virus in 293A celis as shown in figure
40. The resuits of the production of our replicative viral progenies showed that there are
remarkable difference between the titre of our replicative viruses and the first generation
AdVs. We could conclude that the presence of the transgcne in the region between F4
and RTTR instead of the E 1 region had no dilaterious effect on viral progeny. It could be
suggested based on our results that there are different factors involved in decreasing the
viral progeny of our replicative viruses as compared to the Ad wild type. Deletion in E3
region (7), suboptimal expression of P$ under the TK promoter (Gagnon et al., in
preparation) and oversizing viral genome ($3) are the main factors. It has been shown
that the maximum length of inserts that can be introduced in AdVs is limited due to a
tightly controled packaging capacity of the adenovirus capsid. AdV has a theoretical
packaging limit of 3$ Kb, which is 2Kb above its normal size. A study was done with
replication deficient adenoviruses containing expression cassettes of various sizes to
yield oversized AdVs from 106.5% to 108.6% of viral genome (83). Their results
showed an unusually low percentage of recombinants following transfection as well as
considerable genetic instability during amplification and plaque purification. Based on
the publications it is recommended not to oversize the packaging capacity.
4.4 Optimization of the AdV vectors for cancer gene therapy
We could extend our findings to design a potential replicative/nondissiminative
adenovirus for application in cancer therapy. It bas been shown that the delta protease
platform was developed as a tool for applications where high level of transgene is
required (e.g. cancer, vaccination, recombinant protein production, etc) (8). In order to
produce the replicative /nondissiminative AdV expressing the transgene from a region
between F4 and RITR a standard method should be developed via redesigning the
Adeasy system. In this method the transfer vector could be modified to enable us to
introduce the transgene to the region between the F4 and RIIR instead of the Fi region
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and the recombination could occur between the PS deleted Adeasy and the shuttie
vector.
We would design a platform to introduce the gap junction free suicide genes
(eg. CD, CD::UPRT) under the control of a tumor specific promoter (eg. CXCR4, EGP
2, Cox-2 and others). Tumor specific promoters are ernployed to restrict transgene
expression or viral replication in an effective way in order to increase specificity towards
tumor tissues and to reduce adverse effects in non-target tissues. In this design the
desired tumor specific promoter is followed by the cumate operator sequence (CuO)
downstream of the promoter. The CuO operator would allow us to down regulate the
expression of the toxic suicide gene at the step of viral production in 293 CymR cells as
was successftilly done for production of AdTK-IRES-GfP and AdTK-cite-GK viruses.
This cassette is introduced in a region between the E4 and RITR with the orientation
toward the lefi ITR. Our data showed that in our replicative virus platform the deletion
in the E3 and E4 (but orf6 added) regions gives a space of 3.1 Kb and 2.5 Kb
respectively. These deletions would allow us to insert a cassette of about 5.5Kb.
Although it has been shown in several publications that the tumor specific promoters has
been veiy powerful in delivering toxic genes to tumors, the efficacy of our designed
platform should be tested in vivo.
4.5 Conclusion
In conclusion, in our atternpt to develop a new strategy for cancer therapy using
combined suicide gene therapy, we have determined that the better phosphorylation of
GCV via co-expression of GK with 1K was flot a rate- limiting step in tumor ceils
including U87 and 10V 21G cells. We determined that the overexpression of TK
suicide gene in U$7 ceils either by increasing MOI or through replication did not
improve the cytotoxic activity and the bystander effect.
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ANNE)Œ I: Plasmids and viruses used in this study
List of plasmids source
pAdenoVator-CMV5(CuO)TK-IRES-GFP work done in this thesis, unpublished
pAdenoVator—CMV5(CuO)-IRES-GFP Q-biogen, Montreai. Canada
pGT6ocodAupp InvivoGen, San Diego
pBS-TKciteGK vector reference 74
pAdenoVator-CMV5(CuO)mcs Q-biogen, Montreal, Canada
AdenoVator-CMV5(CuO)TK-Cite-GK work done in this thesis, unpublished
pAdE4CR5GFP-R’PS work donc in this thesis, unpublished
pAdE4CR5GFP-L/PS work donc in this thesis. unpubiished
pAdE4ext work donc in our lanoratory, unpublished
pAdCR5GFP work donc in this thesis, unpublished
pAdCR5GFP-R work donc in this thesis, unpublished
pAdCR5GFP-L work donc in this thesis, unpublished
pAdCMV5DCGFPg/TK-PS Gagnon et ai, in preparation
AdE4orf6CR5GFP-R/PS work donc in this thesis, unpublished
Ad E4orf6CR5GFP-L/PS work donc in this thesis, unpublished
pCymR’tk-neo refercnce 33
HSE* PSPAV3 DCGFPg/tk*Hygro Castagner., 2002 unpubiished
List of viruses source
AdCMV5(CuO)TK-IRES-GFP work donc in this thesis, unpublished
AdCMV5(CuO)TK-cite-GK work donc in this thesis, unpublished
Ad(PS)CU-IRES-E1A Bourbeau et ai., in preparation
AdCR5GfP-PJPS work donc in this thesis, unpubiished
AdCR5GFP-L/PS(E3-tk) work donc in this thesis, unpubÏished
AdCR5GfP-R!E4orf6/PS(E3-tk) work donc in this thesis, unpubiished
AdCR5GfP-R/PS work donc in this thcsis, unpublishcd
MCR5GfP-L/EF reference 77
AdCMV5GFP-L/E F reference 33
AdE3-/E4orf6(empty vector) Elahi et ai, in preparation
AdPTG36O2 (Adwt) Ouaiikene et al., 2000
Ad5APS Oualikene et al., 2000
AdcTA reference 33
AdCMV5-Cuo-LacZ reference 33
